Available codes for the GHO dimension:
| Label | ID |
|---|---|
| Ambient air pollution attributable deaths | AIR_1 |
| Ambient air pollution attributable DALYs per 100’000 children under 5 years | AIR_10 |
| Household air pollution attributable deaths | AIR_11 |
| Household air pollution attributable deaths in children under 5 years | AIR_12 |
| Household air pollution attributable deaths per 100’000 capita | AIR_13 |
| Household air pollution attributable deaths per 100’000 children under 5 years | AIR_14 |
| Household air pollution attributable DALYs (’000) | AIR_15 |
| Household air pollution attributable DALYs (’000) in children under 5 years | AIR_16 |
| Household air pollution attributable DALYs per 100’000 capita | AIR_17 |
| Household air pollution attributable DALYs per 100’000 children under 5 years | AIR_18 |
| Population using electricity as main cooking fuel (%) | AIR_19 |
| Ambient air pollution (Annual PM10 [ug/m3]) | AIR_2 |
| Population using LPG as main cooking fuel (%) | AIR_20 |
| Population using natural gas as main cooking fuel (%) | AIR_21 |
| Population using biogas as main cooking fuel (%) | AIR_22 |
| Population using kerosene as main cooking fuel (%) | AIR_23 |
| Population using clean fuels (sum of)(%) | AIR_24 |
| Population using coal as main cooking fuel (%) | AIR_25 |
| Population using charcoal as main cooking fuel (%) | AIR_26 |
| Population using wood as main cooking fuel (%) | AIR_27 |
| Population using dung as main cooking fuel (%) | AIR_28 |
| Population using crop waste as main cooking fuel (%) | AIR_29 |
| Ambient air pollution in urban areas (Annual PM10 [μg/m3]) | AIR_2_1 |
| Ambient air pollution in urban areas (Annual PM2.5 [μg/m3]) | AIR_2_2 |
| Percentage of the total population living in cities > 100’000 inhabitants | AIR_3 |
| Population using solid fuels (sum of) (%) | AIR_30 |
| Population using others (non listed items) as main cooking fuel (%) | AIR_31 |
| Population not cooking (%) | AIR_32 |
| Missing information on cooking fuels (%) | AIR_33 |
| Total survey respondents | AIR_34 |
| Joint effects of air pollution attributable deaths | AIR_35 |
| Joint effects of air pollution attributable deaths in children under 5 years | AIR_36 |
| Joint effects of air pollution attributable deaths per 100’000 capita | AIR_37 |
| Joint effects of air pollution attributable deaths per 100’000 children under 5 years | AIR_38 |
| Percent of urban inhabitants living in cities covered by PM measurements | AIR_3_1 |
| Ambient air pollution attributable deaths in children under 5 years | AIR_4 |
| Household air pollution attributable DALYs | AIR_40 |
| Deaths attributable to ambient air pollution | AIR_41 |
| Deaths attributable to ambient air pollution (age-standardized) | AIR_42 |
| DALYs attributable to ambient air pollution | AIR_43 |
| DALYs attributable to ambient air pollution (age-standardized) | AIR_44 |
| YLLs attributable to ambient air pollution | AIR_45 |
| YLLs attributable to ambient air pollution (age-standardized) | AIR_46 |
| Deaths attributable to ambient air pollution (per 100 000) | AIR_5 |
| Deaths attributable to ambient air pollution (per 100 000, age-standardized) | AIR_50 |
| Ambient air pollution attributable deaths per 100’000 children under 5 years | AIR_6 |
| Ambient air pollution attributable DALYs (’000) | AIR_7 |
| Ambient air pollution attributable DALYs (’000) in children under 5 years | AIR_8 |
| Ambient air pollution attributable DALYs per 100’000 capita | AIR_9 |
| Government unit for treatment | ATLAS_SU_0000000532 |
| Government unit for alcohol and drugs: Location | ATLAS_SU_0000000533 |
| Government unit for alcohol: Location | ATLAS_SU_0000000534 |
| Government unit for drugs: Location | ATLAS_SU_0000000535 |
| No government unit | ATLAS_SU_0000000536 |
| Government unit for mental health/substance use: Location | ATLAS_SU_0000000537 |
| Raised blood pressure (SBP>=140 OR DBP>=90 OR on medication) (crude estimate) | BP_01 |
| Raised blood pressure (SBP>=140 OR DBP>=90 OR on medication) (age-standardized estimate) | BP_02 |
| Raised blood pressure (SBP>=140 OR DBP>=90) (crude estimate) | BP_03 |
| Raised blood pressure (SBP>=140 OR DBP>=90) (age-standardized estimate) | BP_04 |
| Mean systolic blood pressure (crude estimate) | BP_05 |
| Mean systolic blood pressure (age-standardized estimate) | BP_06 |
| Cataract surgical coverage of adults aged 50 and over (%) | CATARACTSURGICAL |
| Effective cataract surgical coverage of adults aged 50 and over (%) | CATARACTSURGICALEFFECTIVE |
| Poverty headcount ratio at $1.25 a day (PPP) (% of population) | CCO_1 |
| Human development index rank | CCO_2 |
| Gender inequality index rank | CCO_3 |
| Literacy rate among adults aged >= 15 years (%) | CCO_WHS9_85 |
| Climate change attributable deaths | CC_1 |
| Climate change attributable DALYs (’000) | CC_2 |
| Climate change attributable deaths per 100’000 capita | CC_3 |
| Climate change attributable DALYs per 100’000 capita | CC_4 |
| Climate change attributable deaths (’000) in children under 5 years | CC_5 |
| Climate change attributable deaths per 100’000 children under 5 years | CC_6 |
| Climate change attributable DALYs (’000) in children under 5 years | CC_7 |
| Climate change attributable DALYs per 100’000 children under 5 years | CC_8 |
| Number of reported cases of cholera | CHOLERA_0000000001 |
| Number of reported deaths from cholera | CHOLERA_0000000002 |
| Cholera case fatality rate | CHOLERA_0000000003 |
| Raised total cholesterol (>= 5.0 mmol/L) (crude estimate) | CHOL_01 |
| Raised total cholesterol (>= 5.0 mmol/L) (age-standardized estimate) | CHOL_02 |
| Mean Total Cholesterol (age-standardized estimate) | CHOL_03 |
| Mean Total Cholesterol (crude estimate) | CHOL_04 |
| Raised total cholesterol (≥ 6.2 mmol/L) (age-standardized estimate) | CHOL_05 |
| Raised total cholesterol (≥ 6.2 mmol/L) (crude estimate) | CHOL_06 |
| Number of under-five deaths (thousands) | CM_01 |
| Number of infant deaths (thousands) | CM_02 |
| Number of neonatal deaths (thousands) | CM_03 |
| Process evaluation was employed to assess implementation | Camp_airtime |
| Formative research was conducted | Camp_aud_research |
| Outcome evaluation was employed to assess effectiveness | Camp_eval_impact |
| Campaign was part of a comprehensive tobacco control programme | Camp_gov_prog |
| Campaign was pre-tested | Camp_mat_tested |
| Campaign utilized media planning | Camp_media_planning |
| At least one national mass media campaign ran during the survey period | Camp_nat |
| Earned media/public relations were used to promote the campaign | Camp_news |
| Campaign aired on television and/or radio | Camp_tv_radio |
| Congenital syphilis number of reported cases | CaseCS |
| Disability-adjusted life years (DALYs), children aged under 5 years (000s) | DALYS04Y000 |
| Disability-adjusted life years (DALYs) per 100 000 population | DALYSPER100000 |
| Disability-adjusted life years (DALYs) total (000s) | DALYSTOTAL |
| Deaths, children aged under 5 years | DEATHS04Y |
| Deaths per 100 000 population | DEATHSPER100000 |
| Deaths total | DEATHSTOTAL |
| Total density per 100 000 population: Hospitals | DEVICES00 |
| Total density per 100 000 population: Health posts | DEVICES01 |
| Total density per 100 000 population: Health centres | DEVICES02 |
| Total density per 100 000 population: District/rural hospitals | DEVICES03 |
| Total density per 100 000 population: Provincial hospitals | DEVICES04 |
| Total density per 100 000 population: Specialized hospitals | DEVICES05 |
| Availability of national standards or recommended lists of medical devices | DEVICES06 |
| Types of lists recommending health technology for high burden diseases | DEVICES07 |
| Total density per million population: Magnetic Resonance Imaging | DEVICES08 |
| Total density per million population: Computed tomography units | DEVICES09 |
| Total density per million population: Positron Emission tomography | DEVICES10 |
| Total density per million population: Gamma camera or Nuclear medicine | DEVICES11 |
| Total density per million population: Linear Accelerator | DEVICES12 |
| Type of nomenclature system | DEVICES13 |
| Use of nomenclature system | DEVICES14 |
| Health technology (medical device) national policy | DEVICES15 |
| Unit in the Ministry of Health responsible for the management of medical devices | DEVICES16 |
| Procurement of medical devices carried out at the national level | DEVICES17 |
| Availability of national list of approved medical devices for procurement or reimbursement | DEVICES18 |
| National guidelines, policies or recommendations on the procurement of medical devices | DEVICES19 |
| Availability of technical specifications of medical devices to support procurement or donations | DEVICES20 |
| Total density per million population: Telecobalt Unit | DEVICES21 |
| Total density per million population: Radiotherapy units | DEVICES22 |
| Total density per million females aged from 50 to 69 years old: Mammography units | DEVICES23 |
| Compliance of ban on promotional discounts | E10_compliance |
| Promotional discounts | E10_promo_discounts |
| Non-tobacco products identified with tobacco brand names | E11_brand_stretching |
| Compliance of ban on non-tobacco goods AND services identified with tobacco brand names | E11_compliance |
| Brand name of non-tobacco products used for tobacco product | E12_brand_sharing |
| Compliance of ban on brand name of non-tobacco products used for tobacco product | E12_compliance |
| Ban on appearance of tobacco brands in TV and/or films (product placement) | E13_brand_placement |
| Compliance of ban on appearance of tobacco brands in TV and/or films (product placement) | E13_compliance |
| Compliance of ban on appearance of tobacco products in TV and/or films | E14_compliance |
| Appearance of tobacco products in TV and/or films | E14_prod_tv_films |
| Compliance of ban on sponsored events | E15_compliance |
| Sponsored events | E15_sponsored_events |
| Publicity of corporate social responsibility activities by tobacco companies | E16_csr_promo_self |
| Publicity of corporate social responsibility activities by other entities | E17_csr_promo_others |
| Tobacco companies funding or making in-kind contributions to smoking prevention media campaigns | E18_csr_anti_tobacco_media |
| Required anti-tobacco ads for any visual entertainment media product that depicts tobacco products, use or images | E19_movies_anti_tob_ads |
| Compliance of ban on advertising on national TV and radio | E1_compliance |
| National television and radio | E1_nat_tv_radio |
| Ban on tobacco vending machines | E21_vending_machines |
| Subnational bans on tobacco advertising, promotion and sponsorship | E22_subnational_exists |
| Subnational advertising, promotion and sponsorship bans - at least one jurisdiction has a comprehensive ban in place | E23_subnat_complete_bans_exist |
| Ban on internet sales of tobacco products | E24_internet_sales_ban |
| Ban on display of tobacco products at points of sale | E25_ban_display_pt_of_sale |
| Law requires fines for violations of direct advertising bans | E26_direct_ad_fines |
| Law requires fines for violations of indirect advertising bans | E27_indirect_ad_fines |
| International television and radio | E2_intl_tv_radio |
| Compliance of ban on advertising on local magazines and newspapers | E3_compliance |
| Local magazines and newspapers | E3_nat_print |
| International magazines and newspapers | E4_intl_print |
| Billboard and outdoor advertising | E5_billboards |
| Compliance of ban on advertising on billboards and outdoor advertising | E5_compliance |
| Compliance of ban on advertising at point of sale | E6_compliance |
| Point of sale | E6_pt_of_sale |
| Internet | E7_internet |
| Compliance of ban on free distribution of tobacco products in the mail or through other means | E9_compliance |
| Free distribution in mail or through other means | E9_free_distrib |
| Compliance with bans on direct advertising | EC_direct_compliance |
| Compliance with bans on promotion and sponsorship | EC_indirect_compliance |
| Electric field (kV/m) | EMFLIMITELECTRIC |
| Electric field limit at 1800 MHz (V/m) | EMFLIMITELECTRIC1800 |
| Electric field limit at 900 MHz (V/m) | EMFLIMITELECTRIC900 |
| Electric field (kV/m) | EMFLIMITELECTRICLF |
| Electric field limit (V/m) | EMFLIMITELECTRICRADIO |
| Electric field (V/m) | EMFLIMITELECTRICRF |
| Magnetic flux density (microT) | EMFLIMITMAGNETIC |
| Power density (W/m^2) | EMFLIMITPOWERDENSITY |
| Power density limit at 1800 MHz (W/m^2) | EMFLIMITPOWERDENSITY1800 |
| Power density limit at 900 MHz (W/m^2) | EMFLIMITPOWERDENSITY900 |
| Limit values | EMFLIMITS |
| Power frequency (Hz) | EMFPOWERFREQUENCY |
| Specific absorption rate (SAR) (W/kg) | EMFSAR |
| Existence of standards | EMFSTANDARD |
| Legislative status | EMFSTATUS |
| Adolescent birth rate (births per 1,000 women aged 15 to 19) | EQ_ADOBIRTH |
| Coverage of antenatal care (4 visits) | EQ_ANC |
| Prevalence of obesity | EQ_BMI30 |
| People who identify the use of condoms as a way to avoid AIDS (%) | EQ_CONDOMUSE |
| Contraceptive prevalence rate among women married or in union | EQ_CONTRACEPTIVE |
| Households with dirt floor (%) | EQ_DIRTFLOOR |
| Coverage of DTP3 immunization | EQ_DTP3 |
| Households with soap and water at a handwashing facility (%) | EQ_HANDWASHING |
| HIV prevalence | EQ_HIVPREV |
| Households that have a bednet for sleeping (%) | EQ_HOUSENETS |
| Infant mortality per 1 000 live births | EQ_INFANTMORT |
| Households with at least one ITN for sleeping (%) | EQ_ITN |
| Children under five who slept under an ITN the previous night (%) | EQ_ITNUNDER5 |
| Knowlege about sexual transmission of AIDS | EQ_KNHIV |
| Coverage of measles immunization | EQ_MEAIMM |
| Population not using any sanitation facility (open defecation) (%) | EQ_OPENDEFECATION |
| Prevalence of (moderate or severe) overweight in children | EQ_OVERWEIGHT |
| Prevalence of overweight and obesity | EQ_OVERWEIGHTADULT |
| Coverage of skilled birth attendance | EQ_SBA |
| Women that slept under a bednet last night (%) | EQ_SLEPTNETS |
| Proportion of urban residents living in a slum area | EQ_SLUM |
| Households that use solid fuels for cooking (%) | EQ_SOLIDFUELS |
| Prevalence of (moderate or severe) stunting in children | EQ_STUNT |
| Prevalence of current cigarette smoking | EQ_TOBACCO |
| Under-five mortality per 1 000 live births | EQ_U5MORT |
| Children under five who slept under a bednet the previous night (%) | EQ_U5SLEPTNETS |
| Prevalence of (moderate or severe) underweight in children | EQ_UNDERWEIGHT |
| Population living in urban areas (%) | EQ_URBPOP |
| Slum population in urban areas (% of total population) | EQ_URBSLUM |
| Population using improved drinking-water sources (%) | EQ_WATER |
| Households using an improved drinking-water source (%) | EQ_WATERIMPROVED |
| Households using a piped drinking-water source (%) | EQ_WATERPIPED |
| Households using a piped onto premises drinking-water source (%) | EQ_WATERPREMISES |
| Enforce bans on tobacco advertising | E_Group |
| Number of deaths | GBD_0000000036 |
| GBD - population | GBD_0000000037 |
| GBD - crude death rate | GBD_0000000038 |
| GBD - Disability-adjusted life years (DALYS) | GBD_76 |
| GBD - Years of life lost (YLL) | GBD_77 |
| GBD - Years lost due to disability (YLD) | GBD_78 |
| Age-standardized death rates (per 100 000 population) | GBD_ASDR |
| DALY rates (per 100,000) | GBD_DALYRT |
| Age-standardized DALYs (per 100,000) | GBD_DALYRTAGE |
| Death rates (per 100,000) | GBD_DTHRT |
| Incidence (in thousands) | GBD_INC |
| Prevalence (in thousands) | GBD_PREV |
| Disability-adjusted life years (DALYs) | GHE_DALYNUM |
| Disability-adjusted life years (DALYs) (per 100 000 population) | GHE_DALYRATE |
| Years of healthy life lost due to disability (YLDs) | GHE_YLDNUM |
| Years of healthy life lost due to disability (YLDs) (per 100 000 population) | GHE_YLDRATE |
| Years of life lost from mortality (YLLs) | GHE_YLLNUM |
| Years of life lost from mortality (YLLs) (per 100 000 population) | GHE_YLLRATE |
| Estimated number of people (all ages) living with HIV | HIV_0000000001 |
| Number of adults aged 15 and over living with HIV | HIV_0000000002 |
| Number of women aged 15 and over living with HIV | HIV_0000000003 |
| Number of children under 15 living with HIV | HIV_0000000004 |
| HIV prevalence rate among adults (15-49) | HIV_0000000005 |
| Number of deaths due to HIV/AIDS | HIV_0000000006 |
| Testing and counselling facilities, reported number | HIV_0000000007 |
| Testing and counselling facilities, estimated number per 100 000 adult population | HIV_0000000008 |
| Reported number of people receiving antiretroviral therapy | HIV_0000000009 |
| Reported number of people receiving antiretroviral therapy, month and year of report | HIV_0000000010 |
| Reported number of children receiving antiretroviral therapy | HIV_0000000011 |
| Reported number of children receiving antiretroviral therapy, month and year of report | HIV_0000000012 |
| Pregnant women tested for HIV, reported number | HIV_0000000013 |
| Pregnant women tested for HIV, estimated coverage (%) | HIV_0000000014 |
| Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission | HIV_0000000015 |
| Number of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission, reporting period | HIV_0000000016 |
| Number of people aged 15 years and over who received HIV testing and counselling, reported number | HIV_0000000017 |
| People aged 15 years and over who received HIV testing and counselling, estimated number per 1000 adult population | HIV_0000000018 |
| Number of people aged 15 years and over who received HIV testing and counselling, reporting period | HIV_0000000019 |
| Estimated percentage of pregnant women living with HIV who received antiretrovirals for preventing mother-to-child transmission | HIV_0000000020 |
| Estimated number of pregnant women living with HIV needing antiretrovirals for preventing mother-to-child transmission based on WHO methods | HIV_0000000021 |
| Estimated number of people eligible for antiretroviral therapy according to 2010 guidelines | HIV_0000000022 |
| Estimated number of children needing antiretroviral therapy based on WHO methods | HIV_0000000023 |
| Estimated antiretroviral therapy coverage among children | HIV_0000000024 |
| Testing and counselling facilities, reporting period | HIV_0000000025 |
| Number of new HIV infections | HIV_0000000026 |
| Estimated antiretroviral therapy coverage among people living with HIV (%) | HIV_ARTCOVERAGE |
| Number of nursing personnel | HRH_01 |
| Number of physicians | HRH_02 |
| Number of midwifery personnel | HRH_03 |
| Number of pharmacists | HRH_04 |
| Number of pharmaceutical technicians/assistants | HRH_05 |
| Number of community health workers | HRH_06 |
| Number of traditional birth attendants | HRH_07 |
| Number of radiographers | HRH_08 |
| Number of other health workers | HRH_09 |
| Number of dental technicians/assistants | HRH_10 |
| Number of health management & support workers | HRH_11 |
| Number of environment and public health workers | HRH_12 |
| Number of laboratory scientists | HRH_13 |
| Number of laboratory technicians/assistants | HRH_14 |
| Number of dentists | HRH_15 |
| Number of traditional medicine practitioners | HRH_16 |
| Number of medical assistants | HRH_17 |
| Number of personal care workers | HRH_18 |
| Number of pharmaceutical personnel | HRH_19 |
| Number of laboratory health workers | HRH_20 |
| Number of dentistry personnel | HRH_21 |
| Number of community and traditional health workers | HRH_22 |
| Number of other health workers | HRH_23 |
| Number of nursing and midwifery personnel | HRH_24 |
| Pharmaceutical personnel density (per 1000 population) | HRH_25 |
| Physicians density (per 1000 population) | HRH_26 |
| Laboratory health workers density (per 1000 population) | HRH_27 |
| Dentistry personnel density (per 1000 population) | HRH_28 |
| Community and traditional health workers density (per 1000 population) | HRH_29 |
| Other health workers density (per 1000 population) | HRH_30 |
| Environmental and public health workers density (per 1000 population) | HRH_31 |
| Health management & support workers density (per 1000 population) | HRH_32 |
| Nursing and midwifery personnel density (per 1000 population) | HRH_33 |
| Biomedical engineers density (per 10 000 population) | HRH_40 |
| Number of licensed qualified surgeons actively working | HRH_41 |
| Number of licensed qualified obstetricians actively working | HRH_42 |
| Number of licensed qualified anaesthesiologists actively working | HRH_43 |
| Handwashing with soap after using the toilet (%) | HWWS_1 |
| Handwashing with soap after cleaning child’s stool (%) | HWWS_2 |
| Legislation | IHR01 |
| Coordination | IHR02 |
| Surveillance | IHR03 |
| Response | IHR04 |
| Preparedness | IHR05 |
| Risk communication | IHR06 |
| Human resources | IHR07 |
| Laboratory | IHR08 |
| Points of entry | IHR09 |
| Zoonosis | IHR10 |
| Food safety | IHR11 |
| Chemical | IHR12 |
| Radionuclear | IHR13 |
| Percentage of sites for which carbamate resistance was reported | IR_CARBAMATE_EXTENT |
| Carbamate resistance reported for at least one site | IR_CARBAMATE_PRESENCE |
| Number of insecticide classes to which resistance was reported | IR_INSECTICIDERESISTANCE_PREV |
| Percentage of sites for which organochlorine resistance was reported | IR_ORGANOCHLORINE_EXTENT |
| Organochlorine resistance reported for at least one site | IR_ORGANOCHLORINE_PRESENCE |
| Percentage of sites for which organophosphate resistance was reported | IR_ORGANOPHOSPHATE_EXTENT |
| Organophosphate resistance reported for at least one site | IR_ORGANOPHOSPHATE_PRESENCE |
| Percentage of sites for which pyrethroid resistance was reported | IR_PYRETHROID_EXTENT |
| Pyrethroid resistance reported for at least one site | IR_PYRETHROID_PRESENCE |
| Percentage of individuals using the Internet | ITU_ICT_1 |
| Mobile-cellular telephone subscriptions per 100 inhabitants | ITU_ICT_2 |
| ICT Development Index (IDI) | ITU_IDI |
| ICT Development Index (IDI) rank | ITU_IDI_RANK |
| Legally binding lead controls | LEADCONTROL |
| Name of legislation for lead controls | LEADCONTROLEGISLATION |
| Description of legislation for lead controls | LEADCONTROLEGISLATIONDESC |
| Percentage of the children under 15 years with blood lead levels above 5ug/dl | LEAD_1 |
| Lead attributable DALYs per 100’000 children under 5 years | LEAD_10 |
| Percentage of the children under 15 years with blood lead levels above 10ug/dl | LEAD_2 |
| Percentage of the adults (15+ years) with blood lead levels above 5ug/dl | LEAD_3 |
| Percentage of the adults (15+ years) with blood lead levels above 10ug/dl | LEAD_4 |
| Lead attributable deaths | LEAD_5 |
| Lead attributable DALYs (’000) | LEAD_6 |
| Lead attributable deaths per 100’000 capita | LEAD_7 |
| Lead attributable DALYs per 100’000 capita | LEAD_8 |
| Lead attributable DALYs (’000) in children under 5 years | LEAD_9 |
| Disability-adjusted life years (DALYs) due to leptospirosis | LEPTO_DALY |
| Disability-adjusted life years (DALYs) (per 100 000 population) due to leptospirosis | LEPTO_DALY100K |
| Estimated leptospirosis incidence (per 100 000 population) | LEPTO_MORBIDITY |
| Estimated leptospirosis deaths (per 100 000 population) | LEPTO_MORTALITY |
| Years of healthy life lost to disability (YLDs) due to leptospirosis | LEPTO_YLD |
| Years of healthy life lost to disability (YLDs) (per 100 000 population) due to leptospirosis | LEPTO_YLD100K |
| Years of life lost (YLLs) due to leptospirosis | LEPTO_YLL |
| Years of life lost (YLLs) (per 100 000 population) due to leptospirosis | LEPTO_YLL100K |
| nMx - age-specific death rate between ages x and x+n | LIFE_0000000029 |
| nqx - probability of dying between ages x and x+n | LIFE_0000000030 |
| lx - number of people left alive at age x | LIFE_0000000031 |
| ndx - number of people dying between ages x and x+n | LIFE_0000000032 |
| nLx - person-years lived between ages x and x+n | LIFE_0000000033 |
| Tx - person-years lived above age x | LIFE_0000000034 |
| ex - expectation of life at age x | LIFE_0000000035 |
| Malaria - number of reported deaths | MALARIA001 |
| Estimated number of malaria cases | MALARIA002 |
| Estimated number of malaria deaths | MALARIA003 |
| Number of under-five deaths from malaria | MALARIA004 |
| Malaria incidence per 100 000 population | MALARIA005 |
| All-cause outpatient cases | MALARIA_15029 |
| All-cause inpatient cases | MALARIA_15030 |
| All-cause inpatient deaths | MALARIA_15031 |
| Total RDT examined | MALARIA_15032 |
| Total RDT positive | MALARIA_15033 |
| Total microscopy examined | MALARIA_15034 |
| Total microscopy positive | MALARIA_15035 |
| Number of P. falciparum | MALARIA_15036 |
| Number of P. vivax | MALARIA_15037 |
| Number of mixed infections | MALARIA_15040 |
| Suspected malaria cases | MALARIA_15043 |
| Malaria outpatient cases | MALARIA_15049 |
| Malaria inpatient cases | MALARIA_15056 |
| Malaria attributed deaths | MALARIA_15059 |
| RDT Positive cases at community level | MALARIA_15063 |
| Number of reported presumed and confirmed malaria cases | MALARIA_15065 |
| ANC first attendance | MALARIA_15077 |
| IPT 1st dose | MALARIA_15079 |
| IPT 2nd dose | MALARIA_15080 |
| IPT 3rd dose | MALARIA_15081 |
| Microscopy slides/RDTs examined | MALARIA_15095 |
| Microscopy slides/RDTs positive | MALARIA_15096 |
| Total number of conventional Insecticide Treated Nets (ITNs) + LLINS sold or delivered | MALARIA_15116 |
| Total number of Long Lasting Insecticide Treated Nets (LLINs) sold or delivered | MALARIA_15117 |
| Spraying cycle | MALARIA_15130 |
| Number of households sprayed at least once | MALARIA_15136 |
| Number of households targeted for spraying | MALARIA_15137 |
| Number people targeted for protection by IRS | MALARIA_15138 |
| Number of people protected by IRS | MALARIA_15139 |
| Number of ACT only treatment doses received (public facilities and community) | MALARIA_15150 |
| Population | MALARIA_15279 |
| Government health budget (USD) | MALARIA_15283 |
| Government budget for malaria (USD) | MALARIA_15284 |
| Contributions from the Global Fund (USD) | MALARIA_15287 |
| Contributions from the Wolrdbank (USD) | MALARIA_15288 |
| European Union (USD) | MALARIA_15309 |
| Gov. expenditure on malaria (USD) | MALARIA_15310 |
| Number of health facility reports received per year (Outpatient) | MALARIA_16201 |
| Number of health facilities (Outpatient) | MALARIA_16202 |
| Number of reports expected per health facility per year (Outpatient) | MALARIA_16203 |
| Number of Admin 2 reports received per year (Outpatient) | MALARIA_16205 |
| Number of Admin 2 units (Outpatient) | MALARIA_16206 |
| Number of reports expected per Admin 2 per year (Outpatient) | MALARIA_16207 |
| RDT tested at community level | MALARIA_16209 |
| Cases at community level (presumed and confirmed) | MALARIA_16210 |
| Examined (by microscopy and RDT)(Active case detection) | MALARIA_16211 |
| Positive (by microscopy and RDT)(Active case detection) | MALARIA_16212 |
| Number of houses or structures targeted | MALARIA_16221 |
| Number of houses or structures sprayed at least once | MALARIA_16222 |
| Number distributed through mass campaign | MALARIA_16223 |
| Number distributed through ANC | MALARIA_16224 |
| Number distributed through EPI | MALARIA_16225 |
| Number distributed through other channels | MALARIA_16226 |
| Number of malaria cases treated with ACT in public facilities | MALARIA_16227 |
| Number of RDTs delivered (public facilities and community) | MALARIA_16228 |
| Number of P. falciparum (RDT test) | MALARIA_16229 |
| Number of other plamodium species (RDT test) | MALARIA_16230 |
| All-cause deaths (including malaria death) (Vital registration) | MALARIA_16231 |
| Malaria deaths (including confirmed deaths) (Vital registration) | MALARIA_16232 |
| Other (NGOs, foundations,etc) | MALARIA_16233 |
| Programme Management (PM) | MALARIA_16234 |
| Entomology and vector control (ITN, IRS, others) | MALARIA_16235 |
| Surveillance, Monitoring and Evaluation (SME) | MALARIA_16236 |
| Diagnosis and case manangement (incl. IPT) | MALARIA_16237 |
| Communications and Advocacy (CAD) | MALARIA_16238 |
| Training | MALARIA_16239 |
| Others | MALARIA_16240 |
| High endemic or risk areas ( RMI > 1) | MALARIA_16252 |
| Low endemic or epidemic-prone areas ( RMI < 1) | MALARIA_16253 |
| Malaria-free areas (no indigenous transmission) | MALARIA_16254 |
| Number of ACT only treatment doses received (public facilities only) | MALARIA_16261 |
| Total number of ACT treatment courses distributed | MALARIA_16262 |
| Number of malaria cases treated with ACT (Community level) | MALARIA_16263 |
| WHO | MALARIA_16264 |
| UNICEF | MALARIA_16265 |
| Other UN agencies | MALARIA_16266 |
| PMI | MALARIA_16267 |
| Other bilaterals | MALARIA_16268 |
| Number of health facility reports received per year (Inpatient) | MALARIA_16270 |
| Number of health facilities (Inpatient) | MALARIA_16271 |
| Number of reports expected per health facility per year (Inpatient) | MALARIA_16272 |
| Number of Admin 2 reports received per year (Inpatient) | MALARIA_16273 |
| Number of Admin 2 units (Inpatient) | MALARIA_16274 |
| Number of reports expected per Admin 2 per year (Inpatient) | MALARIA_16275 |
| Number of conventional insecticide-treated nets (ITNs) sold or delivered | MALARIA_20126 |
| Insecticide used | MALARIA_20129 |
| Total number of 1st line treatment course distributed | MALARIA_20132 |
| Household Net Possession - Percentage with at least one (Any type of mosquito net ) | MALARIA_30514 |
| Household Net Possession - Percentage with more than one (Any type of mosquito net ) | MALARIA_30515 |
| Household Net Possession - Average number of nets per household (Any type of mosquito net ) | MALARIA_30516 |
| Household Net Possession - Percentage with at least one (Ever treated mosquito net ) | MALARIA_30517 |
| Household Net Possession - Percentage with more than one (Ever treated mosquito net ) | MALARIA_30518 |
| Household Net Possession - Average number of ever treated nets per household (Ever treated mosquito net ) | MALARIA_30519 |
| Household Net Possession - Percentage with at least one (Insecticide treated mosquito nets (ITNs) ) | MALARIA_30520 |
| Household Net Possession - Percentage with more than one (Insecticide treated mosquito nets (ITNs) ) | MALARIA_30521 |
| Household Net Possession - Average number of ITNs per household (Insecticide treated mosquito nets (ITNs) ) | MALARIA_30522 |
| Household Net Possession - (Number of households ) | MALARIA_30523 |
| IPT and Anti-malarial Treatment - Percentage who took 2+ doses SP/Fansidar | MALARIA_30526 |
| Prompt Treatment - Percentage who took antimalarial drugs (Among children under age five with fever) | MALARIA_30532 |
| Prompt Treatment - Percentage who took antimalarial drugs same or next day (Among children under age five with fever) | MALARIA_30533 |
| Children with fever - Percentage of children who took drug: SP/ Fansidar | MALARIA_30535 |
| Children with fever - Percentage of children who took drug: Chloroquine | MALARIA_30536 |
| Children with fever - Percentage of children who took drug: Combination with artemisinin | MALARIA_30539 |
| Children with fever - Percentage of children who took drug the same or next day: SP/ Fansidar | MALARIA_30541 |
| Children with fever - Percentage of children who took drug the same or next day: Chloroquine | MALARIA_30542 |
| Children with fever - Percentage of children who took drug the same or next day: Combination with artemisinin | MALARIA_30545 |
| Use of mosquito nets - Percentage of under 5 who slept under any net last night | MALARIA_30548 |
| Use of mosquito nets - Percentage of under 5 who slept under an ever treated net last night | MALARIA_30549 |
| Use of mosquito nets - Percentage of under 5 who slept under an ITN last night | MALARIA_30550 |
| Use of mosquito nets - Number of children under 5 | MALARIA_30555 |
| Use of mosquito nets - Percentage of all women age 15-49 who Slept under any net last night | MALARIA_30556 |
| Use of mosquito nets - Percentage of all women age 15-49 who Slept under an ever treated net last night | MALARIA_30557 |
| Use of mosquito nets - Percentage of all women age 15-49 who Slept under an ITN last night | MALARIA_30558 |
| Use of mosquito nets - Number of pregnant women | MALARIA_30559 |
| Use of mosquito nets - Percentage of pregnant women age 15-49 who Slept under any net last night | MALARIA_30560 |
| Use of mosquito nets - Percentage of pregnant women age 15-49 who Slept under an ever treated net last night | MALARIA_30561 |
| Use of mosquito nets - Percentage of pregnant women age 15-49 who Slept under an ITN last night | MALARIA_30562 |
| Imported cases | MALARIA_40105 |
| Infant mortality rate (probability of dying between birth and age 1 per 1000 live births) | MDG_0000000001 |
| Adolescent birth rate (per 1000 women aged 15-19 years) | MDG_0000000003 |
| Contraceptive prevalence (%) | MDG_0000000005 |
| Contraceptive prevalence, among girls aged 15-19 (%) | MDG_0000000005_AGE1519 |
| Unmet need for family planning (%) | MDG_0000000006 |
| Unmet need for family planning, among girls aged 15-19 (%) | MDG_0000000006_AGE1519 |
| Under-five mortality rate (probability of dying by age 5 per 1000 live births) | MDG_0000000007 |
| Median availability of selected generic medicines (%) - Public | MDG_0000000010 |
| Median consumer price ratio of selected generic medicines - Public | MDG_0000000011 |
| Antiretroviral therapy coverage among people with advanced HIV infection (%) | MDG_0000000012 |
| Children aged <5 years sleeping under insecticide-treated nets (%) | MDG_0000000013 |
| Children aged <5 years with fever who received treatment with any antimalarial (%) | MDG_0000000014 |
| Prevalence of condom use by adults during higher-risk sex (15-49) (%) | MDG_0000000015 |
| Deaths due to malaria (per 100 000 population) | MDG_0000000016 |
| Deaths due to tuberculosis among HIV-negative people (per 100 000 population) | MDG_0000000017 |
| Deaths due to tuberculosis among HIV-positive people (per 100 000 population) | MDG_0000000018 |
| Prevalence of HIV among adults aged >=15 years (per 100 000 population) | MDG_0000000019 |
| Incidence of tuberculosis (per 100 000 population per year) | MDG_0000000020 |
| Population aged 15-24 years with comprehensive correct knowledge of HIV/AIDS (%) | MDG_0000000021 |
| Tuberculosis detection rate under DOTS (%) | MDG_0000000022 |
| Prevalence of tuberculosis (per 100 000 population) | MDG_0000000023 |
| Tuberculosis treatment success under DOTS (%) | MDG_0000000024 |
| Births attended by skilled health personnel (%) | MDG_0000000025 |
| Births attended by skilled health personnel, among girls aged 15-19 (%) | MDG_0000000025_AGE1519 |
| Maternal mortality ratio (per 100 000 live births) | MDG_0000000026 |
| Children aged <5 years stunted (%) | MDG_0000000027 |
| Population below minimum level of dietary energy consumption | MDG_0000000028 |
| Prevalence of HIV among adults aged 15 to 49 (%) | MDG_0000000029 |
| Smear-positive tuberculosis case-detection rate (%) | MDG_0000000030 |
| Smear-positive tuberculosis treatment-success rate (%) | MDG_0000000031 |
| Maternal mortality ratio (per 100 000 live births) - Country reported estimates | MDG_0000000032 |
| Antiretroviral therapy coverage among people with HIV infection eligible for ART according to 2010 guidelines (%) | MDG_0000000033 |
| Antiretroviral therapy coverage among people with advanced HIV infection (%), WHO 2006 guidelines | MDG_0000000034 |
| OOP as a % of THE | MEDS |
| Generic | MEDS0_0_0 |
| Population | MEDS1_01_01 |
| GDP | MEDS1_01_03 |
| Gross domestic product per capita | MEDS1_01_05 |
| Life Expectancy M | MEDS1_02_01 |
| Life Expectancy F | MEDS1_02_02 |
| Infant mortality | MEDS1_02_03 |
| Under 5 Mortality | MEDS1_02_04 |
| NCD mortality rate | MEDS1_02_11 |
| CVD and Diabetes mortality rate | MEDS1_02_12 |
| Cancer mortality rate | MEDS1_02_13 |
| HIV mortality rate | MEDS1_02_14 |
| TB mortality rate | MEDS1_02_15 |
| Malaria mortality rate | MEDS1_02_16 |
| Total Pharmaceutical Expenditure (millions US$) | MEDS201110200 |
| Total Pharmaceutical Expenditure per capita (US$)rate) | MEDS201120200C |
| Share of Total Pharmaceutical Expenditure in Total Health Expenditure (%) | MEDS2011400C |
| Share of Public Pharmaceutical Expenditure in Total Pharmaceutical Expenditure (%) | MEDS2011600C |
| Public Pharmaceutical Expenditure per capita (US$) | MEDS201170200C |
| Market share of generic pharmaceuticals by value (%) | MEDS2012100S |
| Density of pharmacists (per 10 000 population) | MEDS2020200C |
| THE | MEDS2_01_01_02 |
| THE per capita | MEDS2_01_03_02 |
| Public Health Expenditure | MEDS2_01_04_02 |
| Public Health Expenditure as a % of Government Expenditure | MEDS2_01_05 |
| Public Health Expenditure of a % of THE | MEDS2_01_06 |
| Public Health Expenditure per capita | MEDS2_01_07_02 |
| Private Health Expenditure % of THE | MEDS2_01_08 |
| Population covered by a public health service orr insurance plan | MEDS2_01_09 |
| Population covered by private health insurance | MEDS2_01_10 |
| Total pharmaceutical expenditure | MEDS2_01_11_02 |
| Total pharmaceutical expenditure per capita | MEDS2_01_12_02 |
| Share of total pharmaceutical expenditure in gross domestic product (%) | MEDS2_01_13 |
| Share of total pharmaceutical expenditure in total health expenditure (%) | MEDS2_01_14 |
| Share of public pharmaceutical expenditures in total pharmaceutical expenditures (US$) | MEDS2_01_15_02 |
| Share of public pharmaceutical expenditures in total pharmaceutical expenditures (%) | MEDS2_01_15_02_01 |
| Private TPE | MEDS2_01_18_02 |
| Market share of generic pharmaceuticals by value (%) | MEDS2_01_21 |
| OOP as a % of Private Health Expenditure | MEDS2_01_24 |
| Premiums for private health plans as a % of private health expenditure | MEDS2_01_26 |
| Pharmacists | MEDS2_02_01 |
| Density of pharmacist (per 10.000) | MEDS2_02_02 |
| Presence of National Medicines Policy | MEDS3010400 |
| Presence of National Medicines Policy implementation plan | MEDS3010700 |
| Right of access to essential medicines | MEDS3011000 |
| For the pharmaceutical sector | MEDS3011302 |
| Presence of National Health Policy | MEDS3_01_01 |
| NHP Implementation plan exists | MEDS3_01_02 |
| Presence of national medicines policy | MEDS3_01_04 |
| Presence of national medicines policy implementation plan | MEDS3_01_07 |
| Presence of National Clinical Laboratory Policy | MEDS3_01_08 |
| NCLP implementation plan exists | MEDS3_01_09 |
| Right of access to essential medicines | MEDS3_01_10 |
| Official guidelines on medicine donations exist | MEDS3_01_11 |
| Pharmaceutical policy implementation is regularly monitored | MEDS3_01_12_01 |
| Presence of national good governance policy | MEDS3_01_13 |
| Policy to manage conflict of interest issues | MEDS3_01_14 |
| Formal code of conduct for public officials | MEDS3_01_15 |
| Whistle Blowing mechanism | MEDS3_01_16 |
| Market share of domestic manufacturers (%) | MEDS4020300 |
| Legal provision for granting patents on: Pharmaceuticals | MEDS4_01_02_01 |
| Legal provision for granting patents on: Laboratory Supplies | MEDS4_01_02_02 |
| Legal provision for granting patents on: Medical Supplies | MEDS4_01_02_03 |
| Legal provision for granting patents on: Medical Equipment | MEDS4_01_02_04 |
| TRIPS legislated through national legislation | MEDS4_01_04 |
| Trasitional period eligibility | MEDS4_01_06 |
| Compulsory Licensing | MEDS4_01_07_01 |
| Bolar exemption | MEDS4_01_07_02 |
| Parallel importing | MEDS4_01_08 |
| Legal provisions related to: Data exclusivity | MEDS4_01_10 |
| Legal provisions related to: Patent Extension | MEDS4_01_11 |
| Legal provisions for the linkage between patent status and market authorization | MEDS4_01_12 |
| Number of licensed pharmaceutical manufacturers | MEDS4_02_01 |
| Manufacturing capacity: R&D new API | MEDS4_02_02_01 |
| Manufacturing capacity: Production API | MEDS4_02_02_02 |
| Manufacturing capacity: Production formulations | MEDS4_02_02_03 |
| Manufacturing capacity: Repackaging of finished dose forms | MEDS4_02_02_04 |
| Market share of domestic manufacturers by value (%) | MEDS4_02_03 |
| Market share of domestic manufactures by volume (%) | MEDS4_02_05 |
| Existence of formal Medicines Regulatory Authority | MEDS5010200 |
| Website of the formal Medicines Regulatory Authority | MEDS5010700 |
| Market Authorization for all pharmaceutical products required | MEDS5020100 |
| Number of registered pharmaceutical products | MEDS5020600 |
| Registration Fee pharmaceutical containing New Chemical Entity | MEDS5021700S |
| Registration Fee generic pharmaceutical product | MEDS5021800S |
| Inspectors are allowed to inspect premises where pharmaceutical activities are performed | MEDS5030200 |
| Pharmaceutical manufacturers must comply with Good Manufacturing Practices | MEDS5050200 |
| Licensing private pharmacies obligatory | MEDS5050900 |
| National Quality Control Laboratory exists | MEDS5060200 |
| Legal provisions control promoting and advertising of prescription medicine | MEDS5070100 |
| Ban on Direct to Consumer Pharmaceutical Advertising | MEDS5070300 |
| Legal provisions exist requiring authorization for conducting Clinical Trials by the MRA | MEDS5080100 |
| Annual consumption of Morphine (mg/capita) | MEDS5090300 |
| National pharmacovigilance centre linked to the MRA exists | MEDS5100400 |
| Number of reports submitted in the last two year by the pharmacovigilance centre | MEDS5100800 |
| Legal provisions for establishing MRA | MEDS5_01_01 |
| Formal medicines regulatory authority exists | MEDS5_01_02 |
| MRA part of MoH | MEDS5_01_04_01 |
| MRA semi-autonomous | MEDS5_01_04_02 |
| Function of MRA: Market Authorization | MEDS5_01_05_01 |
| Function of MRA: Inspection | MEDS5_01_05_02 |
| Function of MRA: Import Control | MEDS5_01_05_03 |
| Function of MRA: Licensing | MEDS5_01_05_04 |
| Function of MRA: Market control | MEDS5_01_05_05 |
| Function of MRA: Quality control | MEDS5_01_05_06 |
| Function of MRA: Advertising | MEDS5_01_05_07 |
| Function of MRA: Clinical trials | MEDS5_01_05_08 |
| Function of MRA: Pharmacovigilance | MEDS5_01_05_09 |
| Medicines regulatory authority has it own website | MEDS5_01_07 |
| MRA receives external technical assistance | MEDS5_01_08 |
| MRA involved in harmonization / collaboration activities | MEDS5_01_09 |
| Assessment of medicines regulatory system conducted in last 5 years | MEDS5_01_10 |
| Funding of MRA: Government | MEDS5_01_11 |
| Funding of MRA: Fees for service | MEDS5_01_12 |
| Funding of MRA: Other funding | MEDS5_01_13 |
| Funding of MRA: Revenues derived from RA kept in RA | MEDS5_01_14 |
| RA uses computerized information management system | MEDS5_01_15 |
| Market authorization for all pharmaceutical products is required | MEDS5_02_01 |
| Mechnaisms for exceptions / waiver of registration | MEDS5_02_02 |
| Mutual recognition | MEDS5_02_03 |
| Public transparency of criteria for MA application assessment | MEDS5_02_04 |
| WHO prequalification programme information used for product registration | MEDS5_02_05 |
| Number of registered pharmaceuticals | MEDS5_02_06 |
| List of pharmaceuticals with defined periodicity required to be publicly available | MEDS5_02_07 |
| Medicines registration includes INN | MEDS5_02_08 |
| Fee required for Marketing Authorization applications | MEDS5_02_09 |
| Fee for pharmaceuticals containing new chemical entity | MEDS5_02_17 |
| Registration fee generic pharmaceutical product | MEDS5_02_18 |
| Legal provisions for the appointment of government pharmaceutical officials | MEDS5_03_01 |
| Inspectors are allowed to inspect premises where pharmaceutical activities are performed | MEDS5_03_02 |
| Inspection a pre-requisite for licensing of: Public | MEDS5_03_03_01 |
| Inspection a pre-requisite for licensing of: Private | MEDS5_03_03_02 |
| Inspection requirements the same for public and private facilities | MEDS5_03_04 |
| Local manufacturers - GMP compliance | MEDS5_03_05_01 |
| Private Wholesalers | MEDS5_03_05_02 |
| Retail distributors | MEDS5_03_05_03 |
| Public pharmacies and stores | MEDS5_03_05_04 |
| Pharmacies and dispensing points of health facilities | MEDS5_03_05_05 |
| Authorization to import medicines required | MEDS5_04_01 |
| Sampling of imported products for testing permitted | MEDS5_04_02 |
| Importation of medicines through authorized ports of entry | MEDS5_04_03 |
| Inspection of pharmaceutical products at authorized ports of entry permitted | MEDS5_04_04 |
| Licensing required for: Manufacturers | MEDS5_05_01 |
| Pharmaceutical manufacturers must comply good manufacturing practices | MEDS5_05_02 |
| Good Manufacturing Practices (GMP) published | MEDS5_05_03 |
| Licensing required for: Importers | MEDS5_05_04 |
| Licensing required for: Wholesalers | MEDS5_05_05 |
| Wholesalers and distributors to comply with Good Distribution Practices | MEDS5_05_06 |
| National Good Distribution Practice requirements published | MEDS5_05_07 |
| Pharmacists to be registered | MEDS5_05_08 |
| Licensing private pharmacies obligatory | MEDS5_05_09 |
| Licensing required for: public pharmacies | MEDS5_05_10 |
| National Good Pharmacy Practice Guidelines published | MEDS5_05_11 |
| List of all licensed pharmaceutical facilities (publication legally required) | MEDS5_05_12 |
| Legislation supports Pharmaceutical market regulation | MEDS5_06_01 |
| Quality control testing laboratory is available | MEDS5_06_02 |
| Quality control laboratory is part of medication regulatory authority | MEDS5_06_02_01 |
| Testing services contracted out by regulatory authority | MEDS5_06_02_02 |
| For quality monitoring in public sector (pharmacy stores and health facilities) | MEDS5_06_04_01 |
| For quality monitoring in private sector (retail outlets) | MEDS5_06_04_02 |
| When there are complaints / problems | MEDS5_06_04_03 |
| For product registration | MEDS5_06_04_04 |
| For public procurement prequalification | MEDS5_06_04_05 |
| For public program products prior to acceptance and/or distribution | MEDS5_06_04_06 |
| Number of quality control samples tested in past two years | MEDS5_06_06 |
| Number of samples that failed the testing in two years | MEDS5_06_07 |
| Legal provisions control promoting and advertising of prescription medicine | MEDS5_07_01 |
| Ban on direct to consumer pharmaceutical advertising | MEDS5_07_03 |
| Pre-approval for medicines advertisements and promotional materials required | MEDS5_07_04 |
| Guidelines for advertising and promotion of non-prescription medicines | MEDS5_07_05 |
| Code of conduct for advertising by MA holders exists and is publicly available | MEDS5_07_06 |
| Code of conduct applies to: Both | MEDS5_07_06_01 |
| Voluntary adherence to code | MEDS5_07_06_02 |
| Code contains formal process for complaints and sanctions | MEDS5_07_06_03 |
| Up to date list of complaints and sanctions publicly available | MEDS5_07_06_04 |
| Legal provisions exist requiring authorization for conducting clinical trials by the medical regulatory authority | MEDS5_08_01 |
| Clinical Trials require ethics committee/institutional review board approval | MEDS5_08_02 |
| Registration of clinical trials in international/national/regional registry | MEDS5_08_03 |
| Single convention on narcotic drugs, 1961 | MEDS5_09_01_01 |
| The 1972 protocol amending the single convention on narcotic drugs, 1961 | MEDS5_09_01_02 |
| Convention on psychotropic substances, 1971 | MEDS5_09_01_03 |
| United nations convention against the illicit traffic in narcotic drugs and psychotropic substances, 1988 | MEDS5_09_01_04 |
| Laws for the control of narcotic and psychotropic substances, and precursors exist | MEDS5_09_02 |
| Annual morphine consumption (mg/capita) | MEDS5_09_03 |
| PV activities legally established within MRA mandate | MEDS5_10_01 |
| MA holders required to continuously monitor safety of products and report to MRA | MEDS5_10_02 |
| Legal provisions for monitoring of ADR exist | MEDS5_10_03 |
| National pharmacovigilance center linked to the medicines regulatory authority | MEDS5_10_04 |
| Number of reports submitted in the last two years by the national pharmacovigilance center | MEDS5_10_04_02 |
| NPC publishes ADR bulletin | MEDS5_10_04_03 |
| No. of ADRs on database | MEDS5_10_07 |
| Number of reports of adverse drug reactions submitted in the last two years by the national pharmacovigilance center | MEDS5_10_08 |
| No. of ADRs submitted to Uppsala database | MEDS5_10_09_01 |
| Children <5 years receive free medicines | MEDS6010102 |
| Pregnant women receive free medicines | MEDS6010103 |
| All medicines included in the EML | MEDS6010201 |
| Social (health) fund is providing at least partial medicine coverage | MEDS6010300 |
| System in place to monitor prices of medicines | MEDS6030100 |
| Duties on imported active pharmaceutical ingredients | MEDS6060100 |
| Duties on imported finished pharmaceutical products | MEDS6060200 |
| Value Added Tax is levied on finished pharmaceuticals products | MEDS6060300 |
| Patients who cannot afford them received free medicines | MEDS6_01_01_01 |
| Children under 5 receive free medicines | MEDS6_01_01_02 |
| Pregnant women receive free medicines | MEDS6_01_01_03 |
| Elderly received free medicines | MEDS6_01_01_04 |
| All essential medicines are free | MEDS6_01_02_01 |
| Free medicines for any non communicable diseases | MEDS6_01_02_02 |
| Free medicines for Malaria | MEDS6_01_02_03 |
| Free medicines for TB | MEDS6_01_02_04 |
| Free medicines for STD | MEDS6_01_02_05 |
| Free medicines for HIV | MEDS6_01_02_06 |
| Free vaccines for EPI | MEDS6_01_02_07 |
| National or social health insurance providing at least partial medicines coverage | MEDS6_01_03 |
| Providing medicines that are on the Essential Medicines List for inpatients | MEDS6_01_03_01 |
| Providing medicines that are on the Essential Medicines List for outpatients | MEDS6_01_03_02 |
| Private health insurance schemes provide medicines coverage | MEDS6_01_04 |
| Private health insurance provides coverage for medicines which are on the EML | MEDS6_01_04_01 |
| Co-payments/ fee requirements for consultations | MEDS6_02_01 |
| Co-payments/ fee requirements for medicines | MEDS6_02_02 |
| Revenues from fees used to pay salaries of health workers | MEDS6_02_03 |
| Medicine pricing regulations | MEDS6_03_01 |
| Pricing provisions aimed at: Manufacturers | MEDS6_03_01_01 |
| Pricing provisions aimed at: Wholesalers | MEDS6_03_01_02 |
| Pricing provisions aimed at: Retailers | MEDS6_03_01_03 |
| Duties on active pharmaceutical ingredients | MEDS6_06_01 |
| Duties on finished pharmaceutical products | MEDS6_06_02 |
| Value added taxes on pharmaceutical products | MEDS6_06_03 |
| Duty rate on active pharmaceutical ingredients | MEDS6_06_07 |
| Duty rate on finished pharmaceutical products | MEDS6_06_08 |
| Value added taxes rate | MEDS6_06_09 |
| Public sector tender awards are publicly available | MEDS7010400 |
| Availability of key medicines at the Central Medical Store in percentage (%) | MEDS7020900S |
| Public sector procurement is decentralized | MEDS7_01_01_01 |
| Public sector procurement is decentralized and centralized | MEDS7_01_01_02 |
| Public sector procurement is the reponsibility of procurement agency that is part of MOH | MEDS7_01_02_01 |
| Public sector procurement is the reponsibility of procurement agency that is semi autonomous | MEDS7_01_02_02 |
| Public sector procurement is the reponsibility of procurement agency that is autonomous | MEDS7_01_02_03 |
| A government procurement agency procures all public goods | MEDS7_01_02_04 |
| Public sector requests for tender documents are publicly available | MEDS7_01_03 |
| Public sector awards are publicly available | MEDS7_01_04 |
| Procurement is based on prequalification of suppliers | MEDS7_01_05 |
| The government supply system department has a central medical store | MEDS7_02_01 |
| There are national guidelines on Good Distribution Practices | MEDS7_02_03 |
| There is a licensing authority that issues GDP licenses | MEDS7_02_04 |
| The licensing authority accredits public distribution facilities | MEDS7_02_04_01 |
| A list of GDP certified warehouses in the public sector exists | MEDS7_02_05 |
| A list of GDP certified distributors in the public sector exists | MEDS7_02_06 |
| Availability of key medicines at the central medical store | MEDS7_02_09 |
| Legal provisions exist for licensing wholesales in private sector | MEDS7_03_01 |
| Legal provisions exist for licensing distributors in private sector | MEDS7_03_02 |
| A list of GDP certified wholsesalers in the private sector exists | MEDS7_03_03 |
| A list of GDP certified distributors in the private sector exists | MEDS7_03_04 |
| National Essential Medicine List exists | MEDS8010100 |
| Standard Treatment Guidelines for common illnesses are made by Ministry of Health | MEDS8010200 |
| National Standard Treatment Guidelines specific to paediatric conditions exist | MEDS8010500 |
| National Medicines Information Center provides information on medicines | MEDS8010800 |
| Existence of National strategy to contain antimicrobial resistance | MEDS8011200 |
| Public sector | MEDS8021201 |
| Private sector | MEDS8021202 |
| Substitution of generic equivalents at the point of dispensing in public sector facilities is allowed | MEDS8030400 |
| Substitution of generic equivalents at the point of dispensing in private sector facilities is allowed | MEDS8030500 |
| Essential medicines list exists | MEDS8_01_01 |
| Number of medicines on essential medicines list | MEDS8_01_01_01 |
| Written process for selecting medicines on the EML | MEDS8_01_01_02 |
| Written process is publicly available | MEDS8_01_01_03 |
| Mechanism to align EML and STG | MEDS8_01_01_04 |
| Standard treatment guidelines for common illnesses produced by the ministry of health | MEDS8_01_02 |
| STG specific to primary care exists | MEDS8_01_03 |
| STG specific to secondary care exists | MEDS8_01_04 |
| National standard treatment guidelines for children | MEDS8_01_05 |
| % of public health facilities with copy EML (mean) | MEDS8_01_06 |
| % of public health facilities with copy STG (mean) | MEDS8_01_07 |
| National medicines information center exists | MEDS8_01_08 |
| Public education campaigns on rational medicine use topics have been conducted in previous two years | MEDS8_01_09 |
| A survey on rational medicine use has been conducted in the previous two years | MEDS8_01_10 |
| A national committee exists to monitor and promote rational use of medicines | MEDS8_01_11 |
| National strategy to contain antimicrobial resistance exists | MEDS8_01_12 |
| AMR strategy has been updated in 2010 or later | MEDS8_01_12_01 |
| EML includes formulations specific for children | MEDS8_01_14 |
| There are explicitly documented criteria for the selection of medicines on the EML | MEDS8_01_15 |
| There is a formal committee for the selection of products on the EML | MEDS8_01_16 |
| Conflict of interest declarations are required from members of national EML committee | MEDS8_01_16_01 |
| National medicines formulary exists | MEDS8_01_17 |
| Existence of a funded national intersectoral taskforce to coordinate the promotion of appropriate use of antimicrobials | MEDS8_01_18 |
| A national reference lab has responsibility for coordinating epidemiological surveillance of AMR | MEDS8_01_19 |
| Legal provisions exist to govern the licensing and prescribing practices of prescriber | MEDS8_02_01 |
| Legal provisions exist to restrict dispensing by prescribers | MEDS8_02_02 |
| Prescribers in the private sector dispense medicine | MEDS8_02_03 |
| Regulations require hospitals to organize/develop DTCs | MEDS8_02_04 |
| More than half of referral hospital have a DTC | MEDS8_02_05 |
| More than half of general hospitals have a DTC | MEDS8_02_06 |
| More than half of regions/provinces have a DTC | MEDS8_02_07 |
| Core medical training includes: concept of EML | MEDS8_02_08_01 |
| Core medical training includes: Use for STGS | MEDS8_02_08_02 |
| Core medical training includes: Pharmacovigilance | MEDS8_02_08_03 |
| Core medical training includes: Problem based pharmacotherapy | MEDS8_02_08_04 |
| Mandatory continuing education that includes pharmaceutical issues is required for doctors | MEDS8_02_09 |
| Mandatory continuing education that includes pharmaceutical issues is required for nurses | MEDS8_02_10 |
| Mandatory continuing education that includes pharmaceutical issues is required for paramedical staff | MEDS8_02_11 |
| Public sector generic prescribing is obligatory | MEDS8_02_12_01 |
| Private sector generic prescribing is obligatory | MEDS8_02_12_02 |
| Average number of medicines prescribed per patient contact in public health facilities | MEDS8_02_13 |
| % of medicines prescribed in outpatient public health care facilities that are on the EML | MEDS8_02_14 |
| Percentage of medicines in outpatient public health care facilities that are prescribed by INN name | MEDS8_02_15 |
| Percentage of patients in outpatient public health care facilities receiving antibiotics | MEDS8_02_16 |
| Percentage of patients in outpatient public health care facilities receiving injections | MEDS8_02_17 |
| Percentage of medicines adequately labelled in public health facilities | MEDS8_02_19 |
| Diarrhoea in children treated with ORS | MEDS8_02_23 |
| Legal provisions exist to govern dispensing practices of pharmaceutical personnel | MEDS8_03_01 |
| Core pharmacist training includes: EML | MEDS8_03_02_01 |
| Core pharmacist training includes: Use of STG | MEDS8_03_02_02 |
| Core pharmacist training includes: drug information | MEDS8_03_02_03 |
| Core pharmacist training includes: clinical pharmacology | MEDS8_03_02_04 |
| Core pharmacist training includes: medicines supply management | MEDS8_03_02_05 |
| Mandatory continuing education that includes rational use of medicines is required for pharmacists | MEDS8_03_03 |
| Generic substitution permitted in public sector | MEDS8_03_04 |
| Generic substitution permitted in private sector | MEDS8_03_05 |
| Antibiotics are sometimes sold OTC without prescription | MEDS8_03_06 |
| Injectables are sometimes sold OTC without prescription | MEDS8_03_07 |
| Nurses sometimes prescribe prescription-only medicines | MEDS8_03_10_01 |
| Pharmacists sometimes prescribe prescription-only medicines | MEDS8_03_10_02 |
| Paramedics sometimes prescribe prescription-only medicines | MEDS8_03_10_03 |
| Personnel with less than one month training sometimes prescribe prescription-only medicines | MEDS8_03_10_04 |
| Number of suspected meningitis deaths reported | MENING_1 |
| Number of suspected meningitis cases reported | MENING_2 |
| Number of meningitis epidemic districts | MENING_3 |
| Mental health policy | MH_1 |
| Mental health outpatient facilities (per 100,000) | MH_10 |
| Mental health day treatment facilities (per 100,000) | MH_11 |
| Age-standardized suicide rates (per 100 000) | MH_12 |
| Beds for mental health in general hospitals (per 100,000) | MH_13 |
| Community residential facilities (per 100,000) | MH_14 |
| Beds in community residential facilities (per 100,000) | MH_15 |
| Beds in mental hospitals (per 100,000) | MH_16 |
| Mental hospitals (per 100,000) | MH_17 |
| Mental health units in general hospitals (per 100,000) | MH_18 |
| Mental hospital admissions (per 100,000) | MH_19 |
| Mental health plan | MH_2 |
| Outpatient visits (per 100,000) | MH_20 |
| Total workforce in mental health sector (per 100,000) | MH_21 |
| Occupational therapists in mental health sector (per 100,000) | MH_22 |
| Other non-specialized doctors in mental health sector (per 100,000) | MH_23 |
| Mental health units in general hospitals admissions (per 100,000) | MH_24 |
| Stand-alone policy or plan for mental health | MH_25 |
| Stand-alone mental health legislation | MH_3 |
| Government expenditures on mental health as a percentage of total government expenditures on health (%) | MH_4 |
| Government expenditures on mental hospitals as a percentage of total government expenditures on mental health (%) | MH_5 |
| Psychiatrists working in mental health sector (per 100,000) | MH_6 |
| Nurses working in mental health sector (per 100,000) | MH_7 |
| Social workers working in mental health sector (per 100,000) | MH_8 |
| Psychologists working in mental health sector (per 100,000) | MH_9 |
| Number of deaths | MORT_100 |
| Deaths per 1 000 live births | MORT_200 |
| Distribution of causes of death among children aged < 5 years (%) | MORT_300 |
| Deaths per 100 000 population | MORT_400 |
| Number of deaths | MORT_500 |
| Mortality - deaths (country) | MORT_58 |
| Mortality - population (country) | MORT_59 |
| Projection of number of deaths | MORT_600 |
| Mortality - crude death rate per 100 000 population | MORT_61 |
| Mortality - live births (country) | MORT_63 |
| Projection of deaths per 100 000 population | MORT_700 |
| Number of maternal deaths | MORT_MATERNALNUM |
| Current smoking of cigarettes (age-standardized rate) | M_Est_cig_curr |
| Daily smoking of cigarettes (age-standardized rate) | M_Est_cig_daily |
| Current smoking of any tobacco product (age-standardized rate) | M_Est_tob_curr |
| Daily smoking of any tobacco product (age-standardized rate) | M_Est_tob_daily |
| Monitor | M_Group |
| Adult indicator 1 rate | M_def_1_prev_adult |
| Youth indicator 1 rate | M_def_1_prev_youth |
| Adult indicator 1 definition | M_def_1_text_adult |
| Youth indicator 1 definition | M_def_1_text_youth |
| Adult indicator 2 rate | M_def_2_prev_adult |
| Youth indicator 2 rate | M_def_2_prev_youth |
| Adult indicator 2 definition | M_def_2_text_adult |
| Youth indicator 2 definition | M_def_2_text_youth |
| Adult survey age range - smokeless | M_smkless_age_range_adult |
| Youth survey age range - smokeless | M_smkless_age_range_youth |
| Adult smokeless tobacco use indicator definition | M_smkless_def_text_adult |
| Youth smokeless tobacco use indicator definition | M_smkless_def_text_youth |
| Adult smokeless tobacco use indicator rate | M_smkless_prev_adult |
| Youth smokeless tobacco use indicator rate | M_smkless_prev_youth |
| Name of survey of adults - smokeless | M_smkless_survey_title_adult |
| Name of survey of youth - smokeless | M_smkless_survey_title_youth |
| Representativeness of survey of adults - smokeless | M_smkless_svy_national_adult |
| Representativeness of survey of youth - smokeless | M_smkless_svy_national_youth |
| Year of survey of adults - smokeless | M_smkless_svy_yr_adult |
| Year of survey of youth - smokeless | M_smkless_svy_yr_youth |
| Name of survey of adults | M_survey_title_adult |
| Name of survey of youth | M_survey_title_youth |
| Adult survey age range | M_svy_age_adult |
| Youth survey age range | M_svy_age_youth |
| Representativeness of survey of adults | M_svy_national_adult |
| Representativeness of youth survey | M_svy_national_youth |
| Year of survey of adults | M_svy_yr_adult |
| Year of survey of youth | M_svy_yr_youth |
| Probability (%) of dying between exact ages 30 and 70 from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease | NCDMORT3070 |
| BMI >= 25 (age-standardized estimate) | NCD_BMI_25A |
| BMI >= 25 (crude estimate) | NCD_BMI_25C |
| BMI >= 30 (age-standardized estimate) | NCD_BMI_30A |
| BMI >= 30 (crude estimate) | NCD_BMI_30C |
| Mean BMI (kg/m2) (age-standardized estimate) | NCD_BMI_MEAN |
| Mean BMI (kg/m2) (crude estimate) | NCD_BMI_MEANC |
| Cancers, deaths per 100,000 (age-standardized estimate) | NCD_CA |
| Cardiovascular diseases and diabetes, deaths per 100,000 (age-standardized estimate) | NCD_CARDIO |
| General availability of ACE inhibitors in the public health sector | NCD_CCS_ACE |
| General availability of acetic acid visualization at the primary health care level | NCD_CCS_AceticAcid |
| Existence of operational policy/strategy/action plan to reduce the harmful use of alcohol | NCD_CCS_AlcPlan |
| General availability of aspirin (100 mg) in the public health sector | NCD_CCS_Aspirin |
| General availability of beta blockers in the public health sector | NCD_CCS_BetaBlkrs |
| General availability of colon cancer screening at the primary health care level | NCD_CCS_BowelCancer |
| General availability of breast cancer screening (by palpation or mammogram) at the primary health care level | NCD_CCS_BreastCancer |
| General availability of bronchodilators in the public health sector | NCD_CCS_Bronchodilators |
| General availability of CC blockers in the public health sector | NCD_CCS_CCBlkrs |
| Existence of operational policy/strategy/action plan for chronic respiratory diseases | NCD_CCS_CRDPlan |
| Existence of operational policy/strategy/action plan for cardiovascular diseases | NCD_CCS_CVDPlan |
| Existence of operational policy/strategy/action plan for cancer | NCD_CCS_CancerPlan |
| Existence and scope of cancer registry | NCD_CCS_CancerReg |
| Existence of population-based cancer registry | NCD_CCS_CancerRegNational |
| General availability of cervical cytology at the primary health care level | NCD_CCS_CervCy |
| General availability of chemotherapy in the public health system | NCD_CCS_Chemo |
| General availability of total cholesterol measurement at the primary health care level | NCD_CCS_CholMsmt |
| Existence of partnerships/collaborations for implementing key activities related to NCDs | NCD_CCS_Collab |
| Availability and stage of implementation of guidelines/protocols/standards for the management of diabetes | NCD_CCS_DiabGuide |
| Existence of operational policy/strategy/action plan for diabetes | NCD_CCS_DiabPlan |
| Existence of a diabetes registry | NCD_CCS_DiabetesReg |
| General availability of diabetes testing (by blood glucose measurement, OGTT, or HbA1c) at the primary health care level | NCD_CCS_DiabetesTest |
| Existence of operational policy/strategy/action plan to reduce unhealthy diet related to NCDs | NCD_CCS_DietPlan |
| Earmarking of taxes from fiscal interventions to influence behaviour change used to fund health promotion programmes or a health promotion foundation | NCD_CCS_Earmarking |
| General availability of electrocardiogram at the primary health care level | NCD_CCS_Electrocard |
| General availability of glibenclamide in the public health sector | NCD_CCS_Gliben |
| General availability of diabetes testing (by HbA1c) at the primary health care level | NCD_CCS_HbA1c |
| General availability of hydrocortisone injections in the public health sector | NCD_CCS_Hydrocort |
| Availability and stage of implementation of guidelines/protocols/standards for the management of raised blood pressure / hypertension | NCD_CCS_HypGuide |
| General availability of insulin in the public health sector | NCD_CCS_Insulin |
| General availability of ipratropium bromide in the public health sector | NCD_CCS_Ipratro |
| General availability of metformin in the public health sector | NCD_CCS_Metformin |
| Existence of any policies on marketing of foods to children | NCD_CCS_Mkting |
| Existence of a national multisectoral commission, agency or mechanism for NCDs | NCD_CCS_MultisecComm |
| Existence of at least one operational multisectoral national policy, strategy or action plan that integrates several noncommunicable diseases and shared risk factors in conformity with the global/regional noncommunicable disease action plans 2013?2020 | NCD_CCS_MultisecNCDPlan |
| Existence of evidence-based national guidelines/protocols/standards for the management of major NCDs through a primary care approach | NCD_CCS_NCDGuide |
| Existence of a set of national NCD indicators and has set time-bound national targets for these indicators | NCD_CCS_NCDIndicators |
| Existence of Unit, Branch, or Dept. in Ministry of Health with responsibility for NCDs | NCD_CCS_NCDUnit |
| Existence of an Operational Unit, Branch, or Dept. in Ministry of Health with responsibility for NCDs | NCD_CCS_NCDUnit_Operational |
| General availability of nicotine replacement therapy in the public health sector | NCD_CCS_Nicotine |
| General availability of oral morphine in the public health sector | NCD_CCS_OralMorph |
| Existence of operational policy/strategy/action plan to reduce physical inactivity | NCD_CCS_PAPlan |
| Has a STEPS survey or a comprehensive health examination survey every 5 years | NCD_CCS_PM3_Surv |
| General availability of prednisolone tabs in the public health sector | NCD_CCS_Prednis |
| Existence of risk factor surveillance for selected risk factors (harmful alcohol use, diet, physical inactivity, and tobacco use) | NCD_CCS_RFSurv |
| General availability of radiotherapy in the public health system | NCD_CCS_RadioTherapy |
| General availability of renal replacement therapy (by dialysis or transplantation) in the public health system | NCD_CCS_RenalTherapy |
| General availability of retinal photocoagulation in the public health system | NCD_CCS_RetinalPho |
| General availability of salbutamol in the public health sector | NCD_CCS_Salb |
| Existence of any policies to reduce population salt consumption | NCD_CCS_SaltPol |
| Existence of national policies on saturated fatty acids / trans-fats | NCD_CCS_SatFat |
| General availability of peak flow measurement spirometry at the primary health care level | NCD_CCS_Spirom |
| General availability of statins in the public health sector | NCD_CCS_Statins |
| General availability of steroid inhalers in the public health sector | NCD_CCS_Steroid |
| Existence of an NCD surveillance and monitoring system in place to enable reporting against the nine global NCD targets | NCD_CCS_SurvMonRep9NCD |
| General availability of tamoxifen in the public health sector | NCD_CCS_Tamox |
| Implementation of fiscal interventions to influence behaviour change | NCD_CCS_Taxes |
| General availability of thiazide diuretics in the public health sector | NCD_CCS_Thiazide |
| Existence of operational policy/strategy/action plan to decrease tobacco use | NCD_CCS_TobPlan |
| General availability of urine testing for albumin | NCD_CCS_UrineAlbumin |
| General availability of beta blockers in the public health sector | NCD_CCS_betablockers |
| Existence of national screening program for breast cancer | NCD_CCS_breastcancerscreening |
| Most widely used screening method in national cervical cancer screening program | NCD_CCS_cervicalcancermethod |
| Coverage of national cervical cancer screening program (%) | NCD_CCS_cervicalcancerpgmcvg |
| Type of national cervical cancer screening program | NCD_CCS_cervicalcancerpgmtype |
| Existence of national screening program for cervical cancer | NCD_CCS_cervicalcancerscreening |
| General availability of coronary bypass or stenting in the public health system | NCD_CCS_coronary |
| General availability of diabetes testing (by blood glucose measurement, OGTT) at the primary health care level | NCD_CCS_diabtest |
| General availability of dialysis in the public health system | NCD_CCS_dialysis |
| Implementation of diet and/or physical activity public awareness program | NCD_CCS_dietpaaware |
| Existence of national HPV vaccination programme | NCD_CCS_hpv |
| Existence of an operational, multisectoral national NCD policy, strategy or action plan that integrates several NCDs and their risk factors | NCD_CCS_integNCDplan |
| General availability of palliative care in community or home-based care in the public health system | NCD_CCS_palliative_home |
| General availability of palliative care in primary health care in the public health system | NCD_CCS_palliative_prim |
| General availability of retinal photocoagulation in the public health system | NCD_CCS_photocoag |
| General availability of renal replacement by transplantation in the public health system | NCD_CCS_renaltrans |
| Provision for secondary prevention of rheumatic fever and rheumatic heart disease in more than 50% of public sector health facilities | NCD_CCS_rheum |
| Availability of cardiovascular risk stratification in 50% or more primary health care facilities | NCD_CCS_riskstrat |
| Provision for care of acute stroke and rehabilitation in more than 50% of public sector health facilities | NCD_CCS_stroke |
| General availability of sulphonylurea(s) in the public health sector | NCD_CCS_sulphonylurea |
| General availability of thrombolytic therapy in the public health system | NCD_CCS_thrombolytic |
| Chronic respiratory diseases, deaths per 100,000 (age-standardized estimate) | NCD_CHRON |
| All NCDs, deaths per 100,000 (age-standardized estimate) | NCD_DTH_PER |
| Total NCD Deaths | NCD_DTH_TOT |
| Mean fasting blood glucose (mmol/l) (age-standardized estimate) | NCD_GLUC_01 |
| Mean fasting blood glucose (mmol/l) (crude estimate) | NCD_GLUC_02 |
| Raised fasting blood glucose (>= 7.0 mmol/L or on medication) (crude estimate) | NCD_GLUC_03 |
| Raised fasting blood glucose (>=7.0 mmol/L or on medication)(age-standardized estimate) | NCD_GLUC_04 |
| Insufficiently active (age-standardized estimate) | NCD_PAA |
| Insufficiently active (crude estimate) | NCD_PAC |
| Insufficiently active (crude estimate) | NCD_PAC_ADO |
| NCD deaths under age 60 (percent of all NCD deaths) | NCD_UNDER60 |
| NCD deaths under age 70 (percent of all NCD deaths) | NCD_UNDER70 |
| Basis for NHA estimate | NHABASIS |
| General government expenditure on health as percentage of gross domestic product | NHAGGHEGDP |
| Out-of-Pocket expenditure on health as percentage of total health expenditure?? | NHAOOPSTHE |
| Prepaid plans as percentage of total health expenditure? | NHAPREPAIDTHE |
| Number of full-time equivalent staff in national agency | NTCP_FTE |
| National agency for tobacco control exists | NTCP_agcy |
| Budget year | NTCP_budget_year |
| Reported currency | NTCP_curr |
| Annual budget for tobacco control in currency reported | NTCP_govt_exp |
| Government objectives on tobacco control exist | NTCP_govt_obj |
| Budget year | NTCP_usd |
| Number of new reported cases of Buruli ulcer | NTD_1 |
| Dracunculiasis certification status of countries at the beginning of the year | NTD_2 |
| Year country was certified | NTD_2_YEAR_CERTIFIED |
| Annual incidence of dracunculiasis cases | NTD_3 |
| Number of new reported cases of human African trypanosomiasis (T.b. gambiense) | NTD_4 |
| Number of new reported cases of human African trypanosomiasis (T.b. rhodesiense) | NTD_5 |
| Status of elimination of trachoma as a public health problem | NTD_6 |
| Population in areas that warrant treatment with antibiotics, facial cleanliness and environmental improvement for elimination of trachoma as a public health problem | NTD_7 |
| Number of people who received treatment with antibiotics for trachoma | NTD_8 |
| Number of cases of bejel reported | NTD_BEJELNUM |
| Status of bejel endemicity | NTD_BEJELSTATUS |
| Dracunculiasis cases | NTD_DRACASES |
| Status of endemicity of cutaneous leishmaniasis | NTD_LEISHCEND |
| Number of cases of cutaneous leishmaniasis reported | NTD_LEISHCNUM |
| Number of imported cases of cutaneous leishmaniasis reported | NTD_LEISHCNUM_IM |
| Status of endemicity of visceral leishmaniasis | NTD_LEISHVEND |
| Number of cases of visceral leishmaniasis reported | NTD_LEISHVNUM |
| Number of imported cases of visceral leishmaniasis reported | NTD_LEISHVNUM_IM |
| Estimated number of individuals in the country requiring preventive chemotherapy for onchocerciasis | NTD_ONCHEMO |
| Status of endemicity of onchocerciasis | NTD_ONCHSTATUS |
| Reported number of individuals treated for onchocerciasis | NTD_ONCTREAT |
| Number of cases of pinta reported | NTD_PINTANUM |
| Status of pinta endemicity | NTD_PINTASTATUS |
| Reported number of human rabies deaths | NTD_RAB2 |
| Number of people operated for trachomatous trichiasis | NTD_TRA5 |
| Status of yaws endemicity | NTD_YAWSEND |
| Number of cases of yaws reported | NTD_YAWSNUM |
| Overweight numbers (in millions) | NUTOVERWEIGHTNUM |
| Overweight prevalence | NUTOVERWEIGHTPREV |
| Prevalence of adults aged ≥ 15 years who are moderately and severely thin (BMI <17.0) | NUTRITION_0 |
| Prevalence of adults aged ≥ 15 years who are severely thin (BMI <16.0) | NUTRITION_1 |
| Prevalence of adults aged ≥ 15 years who are mildly thin (BMI 17.0-18.49) | NUTRITION_2 |
| Minimum acceptable diet (%) | NUTRITION_2005 |
| Minimum dietary diversity (%) | NUTRITION_2006 |
| Minimum meal frequency (%) | NUTRITION_2007 |
| Prevalence of adults aged ≥ 15 years who are moderately thin (BMI 16.0-16.99) | NUTRITION_3 |
| Children aged <5 years wasted for age (%) | NUTRITION_564 |
| Prevalence of adults aged ≥ 15 years who are pre-obese (%) (BMI 25.0-29.99) | NUTRITION_565 |
| Prevalence of adults aged ≥ 15 years who are overweight (%) (BMI ? 25.0) | NUTRITION_566 |
| Prevalence of adults aged ≥ 15 years who are in normal range (%) (BMI 18.5-24.99) | NUTRITION_567 |
| Prevalence of adults aged ≥ 15 years who are underweight (%) (BMI <18.5) | NUTRITION_568 |
| Continued breastfeeding at 1 year (%) | NUTRITION_569 |
| Early initiation of breastfeeding (%) | NUTRITION_570 |
| Exclusive breastfeeding under 4 months (%) | NUTRITION_571 |
| Continued breastfeeding at 2 years (%) | NUTRITION_572 |
| Children ever breastfed (%) | NUTRITION_573 |
| Duration of any breastfeeding | NUTRITION_574 |
| Duration of exclusive breastfeeding | NUTRITION_575 |
| Introduction of solid, semi-solid or soft foods and breast milk (%) | NUTRITION_576 |
| Bottle feeding rate 0-11.9 months (%) | NUTRITION_577 |
| Bottle feeding rate 0-23.9 months (%) | NUTRITION_578 |
| Exclusive breastfeeding under 6 months (%) | NUTRITION_579 |
| Severe wasting numbers (in millions) | NUTSEVWASTINGNUM |
| Severe wasting prevalence | NUTSEVWASTINGPREV |
| Stunting numbers (in millions) | NUTSTUNTINGNUM |
| Stunting prevalence | NUTSTUNTINGPREV |
| Underweight numbers (in millions) | NUTUNDERWEIGHTNUM |
| Underweight prevalence | NUTUNDERWEIGHTPREV |
| Wasting numbers (in millions) | NUTWASTINGNUM |
| Wasting prevalence | NUTWASTINGPREV |
| Decayed, missing, or filled teeth | OA_DMFT |
| Occupational risk factors attributable deaths | OCC_1 |
| Occupational carcinogens attributable DALYs (’000) | OCC_10 |
| Occupational carcinogens attributable deaths per 100’000 capita | OCC_11 |
| Occupational carcinogens attributable DALYs per 100’000 capita | OCC_12 |
| Occupational noise attributable DALYs (’000) | OCC_13 |
| Occupational noise attributable DALYs per 100’000 capita | OCC_14 |
| Occupational ergonomic stressors attributable deaths | OCC_15 |
| Occupational ergonomic stressors attributable DALYs (’000) | OCC_16 |
| Occupational ergonomic stressors attributable deaths per 100’000 capita | OCC_17 |
| Occupational ergonomic stressors attributable DALYs per 100’000 capita | OCC_18 |
| Occupational injuries attributable deaths | OCC_19 |
| Occupational risk factors attributable DALYs (’000) | OCC_2 |
| Occupational injuries attributable DALYs (’000) | OCC_20 |
| Occupational injuries attributable deaths per 100’000 capita | OCC_21 |
| Occupational injuries attributable DALYs per 100’000 capita | OCC_22 |
| Occupational risk factors attributable deaths per 100’000 capita | OCC_3 |
| Occupational risk factors attributable DALYs per 100’000 capita | OCC_4 |
| Occupational airborne particulates attributable deaths | OCC_5 |
| Occupational airborne particulates attributable DALYs (’000) | OCC_6 |
| Occupational airborne particulates attributable deaths per 100’000 capita | OCC_7 |
| Occupational airborne particulates attributable DALYs per 100’000 capita | OCC_8 |
| Occupational carcinogens attributable deaths | OCC_9 |
| Donor commitments (Million, constant 2009 US$) | ODA_1 |
| Commitments to recipient countries (Million, constant 2009 US$) | ODA_2 |
| Donor disbursements (Million, constant 2009 US$) | ODA_3 |
| Disbursements to recipient countries (Million, constant 2009 US$) | ODA_4 |
| Kidney transplants (absolute number) | ORGANKIDNEYNUM |
| Kidney transplants (per million) | ORGANKIDNEYRATE |
| Liver transplants (absolute number) | ORGANLIVERNUM |
| Liver transplants (per million) | ORGANLIVERRATE |
| Population (millions) | ORGANPOP |
| Total actual deceased donors (absolute number) | ORGANTOTALDECNUM |
| Total actual deceased donors (per million) | ORGANTOTALDECRATE |
| Total organs transplanted (absolute number) | ORGANTOTALNUM |
| Total organs transplanted (per million) | ORGANTOTALRATE |
| Treatment for tobacco dependence available in the community | O_Avail_community |
| Treatment for tobacco dependence available in health clinics or other primary care facilities | O_Avail_hlthSPACEclin |
| Treatment for tobacco dependence available in health clinics or other primary care facilities | O_Avail_hlth_clin |
| Treatment for tobacco dependence available in hospitals | O_Avail_hosp |
| Treatment for tobacco dependence available in offices of health professionals | O_Avail_off_hlth_prof |
| Treatment for tobacco dependence available in other settings | O_Avail_other |
| Bupropion - cost covered | O_Bup_ins |
| Bupropion - legally sold | O_Bup_sold |
| Bupropion - place available | O_Bup_where |
| Offer help to quit tobacco use | O_Group |
| Treatment for tobacco dependence in the community cost covered | O_Ins_community |
| Treatment for tobacco dependence in health clinics or other primary care facilities cost covered | O_Ins_hlth_clin |
| Treatment for tobacco dependence in hospitals cost covered | O_Ins_hosp |
| Treatment for tobacco dependence in offices of health professionals cost covered | O_Ins_off_hlth_prof |
| Treatment for tobacco dependence in other settings cost covered | O_Ins_other |
| Nicotine replacement therapy on the Essential Medicines List | O_NRT_EML |
| Nicotine replacement therapy - cost covered | O_NRT_ins |
| Nicotine replacement therapy - legally sold | O_NRT_sold |
| Nicotine replacement therapy - place available | O_NRT_where |
| Access to a toll-free quit line | O_Quitline |
| Varenicline - cost covered | O_Varen_ins |
| Varenicline - legally sold | O_Varen_sold |
| Varenicline - place available | O_Varen_where |
| Subnational smoke-free legislation authority exists | P10_subnat_auth_exists |
| Fines for violations | P11_fines_any |
| Fines on the establishment | P12_fines_establishment |
| Fines on the patron | P13_fines_smoker |
| Dedicated funds for enforcement | P14_funds_for_enforce |
| Citizen complaints and investigations | P15_complaints |
| Comprehensive bans in place subnationally | P16_subnat_complete_bans_exist |
| Compliance of ban on smoking in HEALTH-CARE FACILITIES | P1_compliance |
| Health-care facilities (national legislation) | P1_healthcare |
| Compliance of ban on smoking in EDUCATIONAL FACILITIES EXCEPT UNIVERSITIES | P2_compliance |
| Education facilities except universities (national legislation) | P2_education |
| Compliance of ban on smoking in UNIVERSITIES | P3_compliance |
| Universities (national legislation) | P3_universities |
| Compliance of ban on smoking in GOVERNMENT FACILITIES | P4_compliance |
| Government facilities (national legislation) | P4_govt |
| Compliance of ban on smoking in INDOOR OFFICES | P5_compliance |
| Indoor offices (national legislation) | P5_indoor_off |
| Compliance of ban on smoking in RESTAURANTS | P6_compliance |
| Restaurants (national legislation) | P6_restaurants |
| Compliance of ban on smoking in PUBS AND BARS | P7_compliance |
| Pubs and bars (national legislation) | P7_pubs |
| Compliance of ban on smoking in PUBLIC TRANSPORT | P8_compliance |
| Public transport (national legislation) | P8_pub_transp |
| All other indoor public places (national legislation) | P9_all_other |
| Compliance with regulations on smoke-free environments (national legislation) | PC_sfe_compliance |
| Prevalence of anaemia in women aged 15-49 (%) | PREVANEMIA |
| Protect from tobacco smoke | P_Group |
| Number of places smoke-free (national legislation) | P_count_places_sf |
| Comprehensive bans in place subnationally | P_subnat_complete_ban_exists |
| Antenatal care attendees who were positive for syphilis (%) | PercposANC |
| Men who have sex with men (MSM) with active syphilis (%) | PercposMSM |
| Sex workers with active syphilis (%) | PercposSW |
| Antenatal care (ANC) attendees tested for syphilis at first ANC visit (%) | PerctestedANC |
| Antenatal care attendees positive for syphilis who received treatment (%) | PerctreatedANC |
| Intimate partner violence prevalence among ever partnered women (%) | RHR_IPV |
| Non-partner sexual violence prevalence (%) | RHR_NPSV |
| Point prevalence (%), alcohol use disorders, 15+ years | RSUD_1 |
| National survey on substance use among children and adolescents | RSUD_10 |
| Data on substance use disorders disseminated in national annual reports | RSUD_11 |
| Substance use policy at the national level | RSUD_12 |
| Substance use policy at the national level, level of integration | RSUD_13 |
| Policy documents on the pharmacological treatment of substance use disorders | RSUD_14 |
| Guidelines on the pharmacological treatment of substance use disorders | RSUD_15 |
| Legislative provision for treatment and rehabilitation of substance use disorders | RSUD_16 |
| Legislative provision for compulsory treatment | RSUD_17 |
| Drug courts | RSUD_18 |
| Programmes diverting clients from the justice system towards treatment | RSUD_19 |
| Point prevalence (%), drug use disorders, 15+ years | RSUD_2 |
| Confidentiality of health records on substance use disorders protected by law | RSUD_20 |
| Government unit for substance use disorder treatment | RSUD_21 |
| Budget line for substance use disorder treatment | RSUD_22 |
| Financing method for substance use disorder treatment | RSUD_23 |
| Treatment services for alcohol use disorders, free of charge | RSUD_24 |
| Treatment services for drug use disorders, free of charge | RSUD_25 |
| Governement benefits for persons with substance use disorders | RSUD_26 |
| Government benefits for alcohol use disorders, subsidy or disability pension | RSUD_27 |
| Government benefits for drug use disorders, subsidy or disability pension | RSUD_28 |
| Sector for inpatient detoxification of alcohol use disorders | RSUD_29 |
| Age-standardized death rates, alcohol and drug use disorders, per 100 000 | RSUD_3 |
| Sector for inpatient treatment of alcohol dependence | RSUD_30 |
| Sector for outpatient treatment of alcohol dependence | RSUD_31 |
| Sector for the treatment of alcohol-induced psychoses and other alcohol-induced psychiatric conditions | RSUD_32 |
| Sector for residential long-term rehabilitation of alcohol use disorders | RSUD_33 |
| Sector for inpatient detoxification of drug use disorders | RSUD_34 |
| Sector for inpatient treatment of drug dependence | RSUD_35 |
| Sector for outpatient treatment of drug dependence | RSUD_36 |
| Sector for substitution maintenance therapy of opioid dependence | RSUD_37 |
| Sector for residential long-term rehabilitation of drug use disorders | RSUD_38 |
| Treatment system for substance use disorders | RSUD_39 |
| Age-standardized death rates, drug use disorders, per 100 000 | RSUD_4 |
| Treatment setting for substance use disorders, most common | RSUD_40 |
| Specialized treatment services for drug use disoders and HIV/AIDS | RSUD_41 |
| Specialized treatment services for substance use disorders and TB | RSUD_42 |
| Open access services for substance use disorders | RSUD_43 |
| Treatment slots for alcohol and drug use disorders, outpatient, per 10 000 | RSUD_44 |
| Beds for the treatment of substance use disorders, per 100 000 | RSUD_45 |
| Length of stay for inpatient detoxification, days | RSUD_46 |
| Length of stay for inpatient short-term treatment, days | RSUD_47 |
| Length of stay for inpatient long-term residential treatment, days | RSUD_48 |
| Opioid agonist pharmacotherapy for the treatment of opioid dependence (detoxification or maintenance) | RSUD_49 |
| Age-standardized DALYs, alcohol and drug use disorders, per 100 000 | RSUD_5 |
| Timeframe of opioid agonist treatment | RSUD_50 |
| Methadone used for the treatment of opioid dependence | RSUD_51 |
| Methadone used for detoxification or maintenance | RSUD_52 |
| Methadone formulation used for the treatment of opiod dependence | RSUD_53 |
| Buprenorphine used for the treatment of opioid dependence | RSUD_54 |
| Buprenorphine used for detoxification or maintenance | RSUD_55 |
| Buprenorphine/naloxone used for the treatment of opioid dependence | RSUD_56 |
| Buprenorphine/naloxone used for detoxification or maintenance | RSUD_57 |
| Methadone provision in clinical and community-based settings | RSUD_58 |
| Buprenorphine provision in clinical and community-based settings | RSUD_59 |
| Age-standardized DALYs, drug use disorders, per 100 000 | RSUD_6 |
| Buprenorphine/naloxone provision in clinical and community-based settings | RSUD_60 |
| Supervision requirements for methadone administration | RSUD_61 |
| Supervision requirements for buprenorphine administration | RSUD_62 |
| Supervision requirements for buprenorphine/naloxone administration | RSUD_63 |
| Prescription requirements for methadone | RSUD_64 |
| Prescription requirements for buprenorphine | RSUD_65 |
| Prescription requirements for buprenorphine/naloxone | RSUD_66 |
| Commencement of treatment with opioid agonists | RSUD_67 |
| Pharmacotherapy used for the management of alcohol withdrawal | RSUD_68 |
| Pharmacotherapy used for the management of benzodiazepine withdrawal | RSUD_69 |
| Psychoactive substance causing entry into treatment | RSUD_7 |
| Pharmacotherapy used for the management of cannabis withdrawal | RSUD_70 |
| Essential list of medicines | RSUD_71 |
| Essential list of medicines, pharmacotherapy for substance use disorders | RSUD_72 |
| Government unit for substance use disorder prevention | RSUD_73 |
| Budget line for substance use disorder prevention | RSUD_74 |
| Funding method for substance use disorder prevention | RSUD_75 |
| Prevention activities for substance use disorders, main focus | RSUD_76 |
| Programmes for the prevention of substance use disorders for special populations | RSUD_77 |
| Screening and brief interventions for substance use and substance use disorders | RSUD_78 |
| Harm reduction programmes for IDUs | RSUD_79 |
| Epidemiological data collection system for substance use disorders | RSUD_8 |
| Health professionals mostly involved in treatment of substance use disorders | RSUD_80 |
| Clinical supervision of health care staff | RSUD_81 |
| Standards of care for health professionals | RSUD_82 |
| Standards of care for health professionals, maintenance | RSUD_83 |
| Standards of care for health professionals, human rights | RSUD_84 |
| NGOs for alcohol use disorders | RSUD_85 |
| NGOs for drug use disorders | RSUD_86 |
| Self-help groups for substance use disorders | RSUD_87 |
| Groups and agencies for the prevention of substance use disorders | RSUD_88 |
| Opioid agonist pharmacotherapy for the treatment of opioid dependence (maintenance) | RSUD_89 |
| Service delivery data collection system for substance use disorders | RSUD_9 |
| Population | RS_1845 |
| Income level | RS_193 |
| Number of registered vehicles | RS_194 |
| Estimated number of road traffic deaths | RS_196 |
| Estimated road traffic death rate (per 100 000 population) | RS_198 |
| Existence of a national drink-driving law | RS_204 |
| Definition of drink-driving by BAC | RS_205 |
| Blood Alcohol Concentration (BAC) limit for drivers | RS_207 |
| Attribution of road traffic deaths to alcohol (%) | RS_208 |
| Existence of a national seat-belt law | RS_209 |
| Applicability of seat-belt law to all occupants | RS_210 |
| Seat-belt wearing rate (%) | RS_212 |
| Existence of a national child-restraint law | RS_213 |
| Existence of national speed limits | RS_214 |
| Adaptation of national speed limit at a local level | RS_215 |
| Specification of national speed law by vehicle type | RS_216 |
| Maximum speed limits | RS_217 |
| Existence of a national motorcycle helmet law | RS_218 |
| Applicability of national motorcycle helmet law to all occupants | RS_219 |
| Applicability of national motorcycle helmet law to all road types | RS_221 |
| Applicability of national motorcycle helmet law to all engine types | RS_222 |
| Requirement of motorcycle helmet use to adhere to standard | RS_223 |
| Law requires helmet to be fastened | RS_223_BIS |
| Motorcycle helmet wearing rate (%) | RS_224 |
| Existence of a road safety lead agency | RS_225 |
| Existence of a national road safety strategy | RS_228 |
| Availability of funding for national road safety strategy | RS_229 |
| Existence of a national policy on walking and cycling | RS_231 |
| Existence of a national policy on public transport | RS_232 |
| Existence of road safety audit for all new roads | RS_233 |
| Existence of road safety audit for existing roads | RS_234 |
| Type of driving tests for new drivers | RS_235 |
| Existence of mandatory vehicle insurance | RS_236 |
| Existence of a formal pre-hospital care system | RS_237 |
| Existence of a universal access telephone number for pre-hospital care | RS_238 |
| Reported % of seriously injured patients transported by ambulance | RS_239 |
| Training in medical emergency - available for doctors | RS_240 |
| Training in medical emergency - available for nurses | RS_241 |
| Vehicle standards | RS_242 |
| Distribution of road traffic deaths by type of road user (%) | RS_246 |
| Gross national income per capita (Atlas method) | RS_576 |
| Average - taxes as a % of cigarette price - ad valorem excise | R_Ad_val_average |
| Most sold brand of cigarettes - taxes as a % of price - ad valorem excise | R_Ad_val_estimate |
| Average - cigarette currency | R_Curr_average |
| Cheapest brand of cigarettes - currency reported | R_Curr_lowest_cost |
| Most sold brand of cigarettes - currency reported | R_Curr_mp |
| Premium brand of cigarettes - currency reported | R_Curr_premium_cost |
| Raise taxes on tobacco | R_Group |
| Average - taxes as a % of cigarette price - other taxes | R_Other_average |
| Most sold brand of cigarettes - taxes as a % of price - other taxes | R_Other_estimate |
| Average - cigarette price in currency | R_Price_average_curr |
| Average - cigarette price in international dollars | R_Price_average_ppp |
| Average - cigarette price in US$ at official exchange rates | R_Price_average_usd |
| Cheapest brand of cigarettes - price in currency reported | R_Price_lowest_estimate |
| Cheapest brand of cigarettes - price in international dollars | R_Price_lowest_ppp |
| Cheapest brand of cigarettes - price in US$ at official exchange rates | R_Price_lowest_usd |
| Most sold brand of cigarettes - price in currency reported | R_Price_mp_estimate |
| Most sold brand of cigarettes - price in international dollars | R_Price_mp_ppp |
| Most sold brand of cigarettes - price in US$ at official exchange rates | R_Price_mp_usd |
| Premium brand of cigarettes - price in currency reported | R_Price_premium_estimate |
| Premium brand of cigarettes - price in international dollars | R_Price_premium_ppp |
| Premium brand of cigarettes - price in US$ at official exchange rates | R_Price_premium_usd |
| Average - taxes as a % of cigarette price - specific excise | R_Sp_excise_average |
| Most sold brand of cigarettes - taxes as a % of price - specific excise | R_Sp_excise_estimate |
| Average - taxes as a % of cigarette price - value added tax | R_VAT_average |
| Most sold brand of cigarettes - taxes as a % of price - value added tax | R_VAT_estimate |
| Tax administration: If duty free imports are limited, duty free allowance (number of cigarette sticks) | R_admin_duty_free_allowance |
| Tax administration: Bans or limits on duty free imports by travellers | R_admin_duty_free_limited |
| Tax administration: Tax stamps applied on tobacco products | R_admin_tax_stamps |
| Affordability: % of GDP per capita required to purchase 100 packs of most sold brand (the higher the %, the less affordable) | R_afford_gdp |
| Affordability: Cigarettes are less affordable in 2014 compared to 2008 | R_afford_less |
| Affordability: Price dispersion: share of cheapest brand price in premium brand price (the higher the % the smaller the gap) | R_afford_price_dispersion |
| Affordability: Specific tax component automatically adjusted for inflation (or other) | R_afford_tax_auto_adjust |
| Tobacco excises increased over the survey period | R_excise_incr |
| Tax structure: Minimum specific tax applied in ad valorem or mixed excise regime | R_excise_min_specific |
| Tax structure: Excise tax proportion of price | R_excise_proportion |
| Tax structure: Retail price used as base of ad valorem component in ad valorem or mixed excise regime (or retail price exclusive of VAT) | R_excise_retail_price_base |
| Tax structure: Greater reliance on specific tax in mixed excise regime | R_excise_specific_reliance |
| Tax structure: Type of excise tax applied | R_excise_type |
| Tax structure: Uniform excise tax | R_excise_uniform_varied |
| Average - taxes as a % of cigarette price - import duties | R_imp_duty_average |
| Most sold brand of cigarettes - taxes as a % of price - import duties | R_imp_duty_estimate |
| Average - taxes as a % of cigarette price - total tax | R_total_tax_average |
| Most sold brand of cigarettes - taxes as a % of price - total tax | R_total_tax_estimate |
| Congenital syphilis rate per 100 000 live births | RateCS |
| Annual tax revenues - value added tax (vat) and other sales taxes | Rev_VAT |
| Annual tax revenues - currency | Rev_curr |
| Annual tax revenues - total excise (specific and ad valorem) | Rev_excise |
| Annual tax revenues - total revenues | Rev_govt_total |
| Annual tax revenues - import duties and all other taxes (excluding corporate taxes on tobacco companies) | Rev_imp_other |
| Annual tax revenues - tobacco products included | Rev_type |
| Annual tax revenues - year | Rev_year |
| Alcohol, consumption of pure alcohol by type of beverage (%) | SA_0000001398 |
| Consumption by type of alcoholic beverage - market share (%) | SA_0000001399 |
| Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol) | SA_0000001400 |
| Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average | SA_0000001401 |
| Alcohol, estimate of five-year change in recorded per capita (15+) consumption 2006-2010 | SA_0000001402 |
| Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) | SA_0000001403 |
| Alcohol, drinkers only (recorded 3 year average + unrecorded) per capita (15+)consumption in litres of pure alcohol | SA_0000001404 |
| Alcohol, tourist consumption (in litres of pure alcohol) | SA_0000001405 |
| Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) | SA_0000001406 |
| Alcohol, abstainers lifetime (%) | SA_0000001409 |
| Abstainers (15-19 years), lifetime (%) | SA_0000001410 |
| Alcohol, abstainers past 12 months (%) | SA_0000001411 |
| Abstainers (15-19 years), past 12 months (%) | SA_0000001412 |
| Alcohol, consumers past 12 months (%) | SA_0000001413 |
| Alcohol, former drinkers (%) | SA_0000001414 |
| Alcohol, heavy episodic drinking (population) past 30 days (%) | SA_0000001415 |
| Alcohol, heavy episodic drinking (drinkers only) past 30 days (%) | SA_0000001416 |
| Alcohol, patterns of drinking score | SA_0000001417 |
| Age-standardized DALYs, alcohol use disorders, per 100,000 | SA_0000001418 |
| Age-standardized DALYs, breast cancer, per 100,000 | SA_0000001419 |
| Age-standardized DALYs, colon and rectum cancers, per 100,000 | SA_0000001420 |
| Age-standardized DALYs, diabetes mellitus, per 100,000 | SA_0000001421 |
| Age-standardized DALYs, drownings, per 100,000 | SA_0000001422 |
| Age-standardized DALYs, falls, per 100,000 | SA_0000001423 |
| Age-standardized DALYs, fires, per 100,000 | SA_0000001424 |
| Age-standardized DALYs, ischaemic heart disease, per 100,000 | SA_0000001425 |
| Age-standardized DALYs, liver cancer, per 100,000 | SA_0000001426 |
| Age-standardized DALYs, liver cirrhosis, per 100,000 | SA_0000001427 |
| Age-standardized DALYs, maternal conditions, per 100,000 | SA_0000001428 |
| Age-standardized DALYs, mouth and oropharynx cancer, per 100,000 | SA_0000001429 |
| Age-standardized DALYs, oesophagus cancer, per 100,000 | SA_0000001430 |
| Age-standardized DALYs, poisoning, per 100,000 | SA_0000001431 |
| Age-standardized DALYs, prematurity and low birth rate, per 100,000 | SA_0000001432 |
| Age-standardized DALYs, road traffic accidents, per 100,000 | SA_0000001433 |
| Age-standardized DALYs, self-inflicted injury, per 100,000 | SA_0000001434 |
| Age-standardized DALYs, other unintentional injuries, per 100,000 | SA_0000001435 |
| Age-standardized DALYs, violence, per 100,000 | SA_0000001436 |
| Age-standardized death rates, alcohol use disorders, per 100,000 | SA_0000001437 |
| Age-standardized death rates, breast cancer, per 100,000 | SA_0000001438 |
| Age-standardized death rates, colon and rectum cancers, per 100,000 | SA_0000001439 |
| Age-standardized death rates, diabetes mellitus, per 100,000 | SA_0000001440 |
| Age-standardized death rates, drownings, per 100,000 | SA_0000001441 |
| Age-standardized death rates, falls, per 100,000 | SA_0000001442 |
| Age-standardized death rates, fires, per 100,000 | SA_0000001443 |
| Age-standardized death rates, ischaemic heart disease, per 100,000 | SA_0000001444 |
| Age-standardized death rates, liver cancer, per 100,000 | SA_0000001445 |
| Age-standardized death rates, liver cirrhosis, per 100,000 | SA_0000001446 |
| Age-standardized death rates, maternal conditions, per 100,000 | SA_0000001447 |
| Age-standardized death rates, mouth and oropharynx cancer, per 100,000 | SA_0000001448 |
| Age-standardized death rates, oesophagus cancer, per 100,000 | SA_0000001449 |
| Age-standardized death rates, poisoning, per 100,000 | SA_0000001450 |
| Age-standardized death rates, prematurity and low birth rate, per 100,000 | SA_0000001451 |
| Age-standardized death rates, road traffic accidents, per 100,000 | SA_0000001452 |
| Age-standardized death rates, self-inflicted injury, per 100,000 | SA_0000001453 |
| Age-standardized death rates, other unintentional injuries, per 100,000 | SA_0000001454 |
| Age-standardized death rates, violence, per 100,000 | SA_0000001455 |
| Age-standardized death rates (15+ years), alcoholic liver disease, per 100,000 | SA_0000001456 |
| Liver cirrhosis, age-standardized death rates (15+), per 100,000 population | SA_0000001457 |
| Age-standardized death rates (15+ years), poisoning, per 100,000 | SA_0000001458 |
| Road traffic crashes, age-standardized death rates (15+), per 100,000 population | SA_0000001459 |
| Age-standardized death rates (15+ years), violence, per 100,000 | SA_0000001460 |
| Alcohol dependence (15+ ), 12-month prevalence (%) with 95%CI | SA_0000001461 |
| Alcohol use disorders (15+), 12 month prevalence (%) with 95% | SA_0000001462 |
| Alcoholic psychosis, incidence, per 100,000 | SA_0000001463 |
| Cautions and arrests for drink-driving, per 100,000 population | SA_0000001464 |
| Hospital discharges, alcohol-related injuries and poisoning, per 100,000 | SA_0000001465 |
| Hospital discharges, alcoholic liver disease, per 100,000 | SA_0000001466 |
| Perceived trend in alcohol-related harm and consequences | SA_0000001467 |
| Treatment admissions (inpatient), alcohol dependence, per 100,000 | SA_0000001468 |
| Treatment admissions (inpatient), alcoholic psychosis, per 100,000 | SA_0000001469 |
| Alcohol-related road traffic crashes, per 100,000 population | SA_0000001470 |
| Alcohol-related road traffic crashes (% of all traffic crashes) | SA_0000001471 |
| Alcohol-related injury mortality, per 1,000 | SA_0000001472 |
| Alcohol-related disease mortality, per 100,000 (15+ years) | SA_0000001473 |
| Alcoholic excise tax revenue as a per cent of government revenue | SA_0000001474 |
| Annual revenues from alcohol excise tax in millions US$ | SA_0000001475 |
| Alcohol expenditure as a per cent of total household expenditure | SA_0000001476 |
| Social costs of alcohol use in millions US$ | SA_0000001477 |
| Adopted written national policy on alcohol | SA_0000001502 |
| Alcoholic beverage legally defined | SA_0000001503 |
| Alcohol use is banned | SA_0000001504 |
| Surrogate alcohol consumption is a problem | SA_0000001505 |
| National legislation to prevent illegal alcohol | SA_0000001506 |
| Advertising restrictions on national television | SA_0000001507 |
| Advertising restrictions on cable television | SA_0000001508 |
| Advertising restrictions on national radio | SA_0000001509 |
| Advertising restrictions on local radio | SA_0000001510 |
| Advertising restrictions in print media | SA_0000001511 |
| Advertising restrictions at cinemas | SA_0000001512 |
| Advertising restrictions on billboards | SA_0000001513 |
| Advertising restrictions at point-of-sale | SA_0000001514 |
| Advertising restrictions on the internet | SA_0000001515 |
| Restrictions on product placement on national television | SA_0000001516 |
| Restrictions on product placement on cable television | SA_0000001517 |
| Age limits on-premise service | SA_0000001518 |
| Minimum legal drinking age | SA_0000001519 |
| Legal blood alcohol concentration (BAC) limits | SA_0000001520 |
| Random breath testing (RBT) use | SA_0000001521 |
| Mandatory driver education for habitual offenders | SA_0000001522 |
| Prices for alcoholic beverages (average, US$) | SA_0000001523 |
| Trend in real price of alcoholic beverages relative to CPI over the past five years | SA_0000001524 |
| Off-premise sales restrictions on days | SA_0000001525 |
| Off-premise sales restrictions on hours | SA_0000001526 |
| Off-premise sales restrictions on places | SA_0000001527 |
| Off-premise sales restrictions on outlet density | SA_0000001528 |
| Off-premise sales restrictions at specific events | SA_0000001529 |
| Off-premise sales restrictions at petrol stations | SA_0000001530 |
| On-premise sales restrictions on days | SA_0000001531 |
| On-premise sales restrictions on hours | SA_0000001532 |
| On-premise sales restrictions on places | SA_0000001533 |
| On-premise sales restrictions on outlet density | SA_0000001534 |
| On-premise sales restrictions at specific events | SA_0000001535 |
| On-premise sales restrictions to intoxicated persons | SA_0000001536 |
| Restrictions on sponsorship of sporting events | SA_0000001537 |
| Restrictions on sponsorship of youth events | SA_0000001538 |
| Restrictions on sales promotion from producers (parties, events) | SA_0000001539 |
| Restrictions on sales promotion from retailers (sales below cost) | SA_0000001540 |
| Restrictions on sales promotion from owners of pubs and bars (alcohol for free) | SA_0000001541 |
| Government monopoly on production | SA_0000001542 |
| Government monopoly on retail sales | SA_0000001543 |
| Licence required for production | SA_0000001544 |
| Licence required for retail sales | SA_0000001545 |
| Excise tax as a per cent of the retail price of alcoholic beverages | SA_0000001546 |
| Excise duty (average) per hectolitre in Euros | SA_0000001547 |
| Excise tax as a per cent of the total retail price for 1 litre of pure alcohol | SA_0000001548 |
| Duty paid or excise stamp on alcohol container | SA_0000001549 |
| Excise tax on alcoholic beverages | SA_0000001550 |
| Value-added tax (VAT) on alcohol (%) | SA_0000001551 |
| Value-added tax (VAT), (%) | SA_0000001552 |
| Restrictions on alcohol use in public places | SA_0000001553 |
| Health warning labels on alcohol advertising | SA_0000001554 |
| Health warning labels on alcohol containers | SA_0000001555 |
| Awareness activities | SA_0000001647 |
| Information, education, prevention | SA_0000001648 |
| National drinking guidelines | SA_0000001649 |
| Standard drink measures, in grams per unit | SA_0000001650 |
| Monitoring | SA_0000001651 |
| Interventions, projects, training | SA_0000001652 |
| Treatment, services | SA_0000001653 |
| Surveys, research | SA_0000001654 |
| Counselling | SA_0000001655 |
| Production in 1000s hectolitres | SA_0000001676 |
| Imports in 1000s hectolitres | SA_0000001677 |
| Sales of beer in 1000s hectolitres | SA_0000001678 |
| Exports of beer (barley) in 1000s hectolitres | SA_0000001679 |
| Perceived trend in production | SA_0000001680 |
| Perceived trend in imports | SA_0000001681 |
| Perceived trend in sales | SA_0000001682 |
| Perceived trend in exports | SA_0000001683 |
| Sales of wine in 1000s hectolitres | SA_0000001684 |
| Sales of spirits in 1000s hectolitres | SA_0000001685 |
| Exports of wine (grape) in 1000s hectolitres | SA_0000001686 |
| Exports of spirits in 1000s hectolitres | SA_0000001687 |
| Projections for total (recorded + unrecorded) alcohol per capita (15+) consumption | SA_0000001688 |
| Age-standardized DALYs, cerebrovascular disease, per 100,000 | SA_0000001689 |
| Age-standardized death rates, cerebrovascular disease, per 100,000 | SA_0000001690 |
| Central coordinating entity for alcohol policy implementation | SA_0000001691 |
| Framework of national alcohol policy | SA_0000001692 |
| Level of adoption of national alcohol policy | SA_0000001693 |
| Sectors represented in national alcohol policy | SA_0000001694 |
| Cautions and arrests for public drunkenness, per 100,000 population | SA_0000001695 |
| Alcohol-related road traffic crashes with fatalities (% of all road traffic crashes with fatalities) | SA_0000001696 |
| Adopted written national policy on alcohol, year adopted | SA_0000001697 |
| Adopted written national policy on alcohol, year revised | SA_0000001698 |
| Age limits off-premise sales | SA_0000001699 |
| Consumer information on alcohol and health at points of sale | SA_0000001700 |
| Educational programmes involving target groups in school curriculum | SA_0000001701 |
| Brief interventions as health promotion/disease prevention | SA_0000001702 |
| Server training on a regular basis | SA_0000001703 |
| Data collection on alcohol-related health indicators | SA_0000001704 |
| System for monitoring alcohol-related harm | SA_0000001705 |
| National treatment policy for alcohol use disorders | SA_0000001706 |
| Persons with alcohol use disorders receiving treatment (%) | SA_0000001707 |
| Designation of alcohol tax revenues to health services | SA_0000001708 |
| National surveys on drink-driving | SA_0000001709 |
| Public-funded alcohol research/monitoring programmes | SA_0000001710 |
| Public funds designated for alcohol research/monitoring programmes, in Euros | SA_0000001711 |
| Community-based interventions/projects involving stakeholders | SA_0000001712 |
| Interventions/projects actively involving young people and civil society | SA_0000001713 |
| Training in screening and brief interventions for alcohol problems | SA_0000001714 |
| Counselling to children in families with alcohol problems | SA_0000001715 |
| Counselling to pregnant women with alcohol problems | SA_0000001716 |
| Prevention/counselling at workplaces for those with alcohol problems | SA_0000001717 |
| Action Plan for implementation of alcohol policy | SA_0000001718 |
| Advertising restrictions on social media | SA_0000001719 |
| Restrictions on product placement in films/movies | SA_0000001720 |
| Importance of measures for enhancing compliance with age limits | SA_0000001721 |
| Government support for community action | SA_0000001722 |
| Community-based interventions involving stakeholders | SA_0000001723 |
| National guidelines for implementing effective community-based interventions | SA_0000001724 |
| National alcohol policy specifically involves young people activities | SA_0000001725 |
| Penalties for drink driving | SA_0000001726 |
| Sobriety checkpoints | SA_0000001727 |
| Detection of marketing infringements | SA_0000001728 |
| Penalties for marketing infringements | SA_0000001729 |
| Price measures | SA_0000001730 |
| Level of taxation adjusted for inflation | SA_0000001731 |
| New types of alcoholic beverages emerging | SA_0000001732 |
| Consumer information about calories, additives, etc on containers | SA_0000001733 |
| Number of standard alcoholic drinks displayed on containers | SA_0000001734 |
| Alcohol content displayed on containers | SA_0000001735 |
| Action Plan for implementation of alcohol policy | SA_0000001736 |
| Alcohol, regional per capita (15+) consumption (in litres of pure alcohol) | SA_0000001737 |
| Regional alcohol per capita (15+) consumption- total | SA_0000001738 |
| Alcohol, heavy episodic drinking (population) past 30 days (%), age-standardized with 95%CI | SA_0000001739 |
| Alcohol-attributable Years of Life Lost (YLL) score | SA_0000001740 |
| Alcohol-attributable fractions (15+), liver cirrhosis deaths (%) | SA_0000001741 |
| Alcohol-attributable fractions (15+), road traffic crash deaths (%) | SA_0000001742 |
| Alcohol-attributable fractions, all-cause deaths (%) | SA_0000001743 |
| Alcohol, regional prevalence of alcohol dependence (%) | SA_0000001744 |
| Alcohol, regional prevalence of alcohol use disorders (%) | SA_0000001745 |
| Alcohol, total (recorded + unrecorded) per capita (15+) consumption with 95%CI, projections to 2025 | SA_0000001746 |
| Alcohol, recorded per capita (15+) consumption (in litres of pure alcohol), three-year average with 95%CI | SA_0000001747 |
| Alcohol, unrecorded per capita (15+) consumption (in litres of pure alcohol) with 95%CI | SA_0000001748 |
| Alcohol, total (recorded 3 year average + unrecorded) per capita (15+) consumption (in litres of pure alcohol) with 95%CI | SA_0000001749 |
| Average daily intake in grams of alcohol among drinkers | SA_0000001750 |
| Alcohol, average daily intake in grams among drinkers with 95%CI | SA_0000001751 |
| Alcohol, total (recorded + unrecorded) per capita (15+) consumption, projected estimates for 2012 | SA_0000001752 |
| Alcohol use disorders (15+), 12 month prevalence (%), age standardized, with 95%CI | SA_0000001753 |
| Alcohol, harmful use (15+), 12 month prevalence (%) with 95%CI | SA_0000001754 |
| 15-19 years old heavy episodic drinkers (population), % with 95%CI | SA_0000001755 |
| 15-19 years old heavy episodic drinkers (drinkers only), % | SA_0000001756 |
| 15-19 years old abstainers, lifetime (%) | SA_0000001757 |
| 15-19 years old former drinkers (%) | SA_0000001758 |
| 15-19 years old, current drinkers (%) | SA_0000001759 |
| 15-19 years old total alcohol consumption in litres of pure alcohol | SA_0000001760 |
| National guidelines for the prevention and reduction of alcohol-related harm in schools | SA_0000001761 |
| National guidelines for alcohol problem prevention and counselling at workplaces | SA_0000001762 |
| Workplace representatives nationally involved to prevent and address alcohol-related harm | SA_0000001763 |
| Server training | SA_0000001764 |
| Legal obligation for schools to include alcohol use prevention | SA_0000001765 |
| Legal obligation for schools to interact with parents regarding education and well-being | SA_0000001766 |
| Legislation on alcohol testing at workplaces | SA_0000001767 |
| Standard drink defined | SA_0000001768 |
| National sytems for monitoring alcohol consumption and harms | SA_0000001769 |
| Regular reports from national monitoring systems | SA_0000001770 |
| Comprehensive and regular reporting of alcohol situation | SA_0000001771 |
| Clinical guidelines for brief interventions | SA_0000001772 |
| National surveys on adult alcohol consumption | SA_0000001773 |
| National surveys on youth alcohol consumption | SA_0000001774 |
| National surveys on heavy espisodic drinking | SA_0000001775 |
| Data collection on Foetal Alcohol Syndome | SA_0000001776 |
| Data collected on harm from alcohol at workplace | SA_0000001777 |
| New types of alcoholic beverages emerging | SA_0000001778 |
| Level of enforcement of BAC limits | SA_0000001779 |
| 15-years old any alcoholic beverage consumed at least once in lifetime, (%) | SA_0000001780 |
| 15-years old any alcoholic beverage consumed in past 12 months, (%) | SA_0000001781 |
| 15-years old first drink at 13 years or younger, (%) | SA_0000001782 |
| 15-years old any alcoholic beverage consumed in past 30 days, (%) | SA_0000001783 |
| 15-years old, any alcoholic beverage consumed at least once a week, (%) | SA_0000001784 |
| 15-years old ever got drunk in the past 30 days, (%) | SA_0000001785 |
| 13-15-years old any alcoholic beverage consumed in past 30 days, (%) | SA_0000001786 |
| 13-15-years old first drink before age 14, (%) | SA_0000001787 |
| Alcohol-related road traffic crashes with fatalities, per 100,000 population | SA_0000001788 |
| Adolescent birth rate (births per 1 000 women aged 15-19) | SDGABR |
| Mortality rate attributed to household and ambient air pollution (per 100 000 population) | SDGAIRBOD |
| Age-standardized mortality rate attributed to household and ambient air pollution (per 100 000 population) | SDGAIRBODA |
| Estimated direct deaths from major conflicts (per 100 000 population) | SDGCONFLICT |
| Average death rate due to natural disasters (per 100 000 population) | SDGDISASTER |
| Married or in-union women of reproductive age who have their need for family planning satisfied with modern methods (%) | SDGFP |
| New HIV infections among adults 15-49 years old (per 1000 uninfected population) | SDGHIV |
| Average of 13 International Health Regulations core capacity scores | SDGIHR |
| Malaria incidence (per 1 000 population at risk) | SDGMALARIA |
| Reported number of people requiring interventions against NTDs | SDGNTDTREATMENT |
| Out-of-pocket expenditure as a percentage of total expenditure on health | SDGOOP |
| Concentrations of fine particulate matter (PM2.5) | SDGPM25 |
| Mortality rate from unintentional poisoning (per 100 000 population) | SDGPOISON |
| Proportion of population with primary reliance on clean fuels (%) | SDGPOLLUTINGFUELS |
| Age-standardized road traffic mortality (per 100 000 population) | SDGROADAGE |
| Proportion of births attended by skilled health personnel (%) | SDGSAB |
| Skilled health professionals density (per 10 000 population) | SDGSHP |
| Crude suicide rates (per 100 000 population) | SDGSUICIDE |
| Age-standardized prevalence of current tobacco smoking among persons aged 15 years and older | SDGTOBACCO |
| Mortality rate attributed to exposure to unsafe WASH services (per 100 000 population) | SDGWSHBOD |
| Percentage of children under 15 years exposed to second-hand smoke | SHS_1 |
| Second-hand smoke attributable DALYs (’000) in children under 5 years | SHS_10 |
| Second-hand smoke attributable DALYs per 100’000 children under 5 years | SHS_11 |
| Percentage of women (15+ years) exposed to second-hand smoke | SHS_2 |
| Percentage of men (15+ years) exposed to second-hand smoke | SHS_3 |
| Second-hand smoke attributable deaths | SHS_4 |
| Second-hand smoke attributable DALYs (’000) | SHS_5 |
| Second-hand smoke attributable deaths per 100’000 capita | SHS_6 |
| Second-hand smoke attributable DALYs per 100’000 capita | SHS_7 |
| Second-hand smoke attributable deaths (’000) in children under 5 years | SHS_8 |
| Second-hand smoke attributable deaths per 100’000 children under 5 years | SHS_9 |
| Existence of sunbed regulations | SUNBEDEXIST |
| Year of implementation of sunbed regulations | SUNBEDEXISTYEAR |
| Access restrictions | SUNBEDREG_ACCESS |
| Restriction and inspection of facilities | SUNBEDREG_CONTROL |
| Information requirements | SUNBEDREG_INFO |
| Safety requirements | SUNBEDREG_SAFETY |
| Training requirements | SUNBEDREG_TRAINING |
| Tuberculosis treatment coverage | TB_1 |
| Case detection rate for all forms of tuberculosis | TB_8_c_cdr |
| New cases tested for RR-/MDR-TB (%) | TB_c_dst_rlt_new_pct |
| Previously treated cases tested for RR-/MDR-TB (%) | TB_c_dst_rlt_ret_pct |
| Laboratories providing tuberculosis diagnostic services using culture (per 5 million population) | TB_c_lab_cul_5m |
| Laboratories providing drug susceptibility testing (DST) (per 5 million population) | TB_c_lab_dst_5m |
| Laboratories providing tuberculosis diagnostic services using sputum smear microscopy (per 100 000 population) | TB_c_lab_sm_100k |
| Treatment success rate for patients treated for MDR-TB (%) | TB_c_mdr_tsr |
| Cases started on MDR-TB treatment | TB_c_mdr_tx |
| Treatment success rate for new pulmonary smear-negative and extrapulmonary tuberculosis cases | TB_c_new_snep_tsr |
| Treatment success rate: new TB cases | TB_c_new_tsr |
| Tuberculosis - new and relapse cases | TB_c_newinc |
| Total number of notified TB cases | TB_c_notified |
| Treatment success rate: previously treated TB cases | TB_c_ret_tsr |
| Treatment success rate: HIV-positive TB cases | TB_c_tbhiv_tsr |
| Treatment success rate (new smear-positive cases) | TB_c_tsr |
| Treatment success rate: XDR-TB cases | TB_c_xdr_tsr |
| Confirmed cases of MDR-TB started treatment for MDR-TB (%) | TB_conf_mdr_tx_pct |
| Number of incident tuberculosis cases | TB_e_inc_num |
| Incidence of tuberculosis (per 100 000 population) (HIV-positive cases) | TB_e_inc_tbhiv_100k |
| Number of incident tuberculosis cases, (HIV-positive cases) | TB_e_inc_tbhiv_num |
| Estimated MDR-TB cases among notified pulmonary TB cases | TB_e_mdr_num |
| Mortality of TB cases (all forms, excluding HIV) per 100 000 population | TB_e_mort_exc_tbhiv_100k |
| Number of deaths due to tuberculosis, excluding HIV | TB_e_mort_exc_tbhiv_num |
| Number of deaths from TB (all forms, excluding HIV) | TB_e_mort_exc_tbhiv_num_save |
| Number of prevalent tuberculosis cases | TB_e_prev_num |
| Estimated MDR/RR-TB cases among notified pulmonary TB cases | TB_e_rr_in_notified_pulm |
| % of patients treated with fixed-dose combinations (FDCs) | TB_fdc_pcnt |
| HIV-positive TB patients on ART (antiretroviral therapy) (%) | TB_hiv_art_pct |
| HIV-positive TB patients on CPT (co-trimoxazole preventive therapy) (%) | TB_hiv_cpt_pct |
| TB patients with known HIV status (%) | TB_hivtest_pct |
| Tested TB patients HIV-positive (%) | TB_hivtest_pos_pct |
| Confirmed cases of MDR-TB | TB_mdr |
| New or unknown treatment history cases: Pulmonary, clinically diagnosed | TB_new_clindx |
| New cases: extrapulmonary | TB_new_ep |
| New or unknown treatment history cases: Pulmonary, bacteriologically confirmed | TB_new_labconf |
| New cases: other | TB_new_oth |
| New cases: pulmonary smear-negative | TB_new_sn |
| New cases: Pulmonary, smear-negative/unknown/not done and other new cases | TB_new_snsuoth |
| TB_new_snuoth | TB_new_snuoth |
| New cases: Pulmonary, smear-positive | TB_new_sp |
| New cases: pulmonary smear unknown/not done | TB_new_su |
| Tuberculosis - new and relapse cases | TB_newinc |
| Treatment history unknown | TB_newret_oth |
| National Reference Laboratory (NRL) | TB_nrl |
| Paediatric formulations procured for TB patients | TB_paed_form |
| Rifampicin used throughout treatment | TB_r_rgmn_new_initcont |
| Previously treated cases, excluding relapse | TB_ret_nrel |
| Retreatment cases: other | TB_ret_oth |
| Relapse cases (pre-2013 definition) | TB_ret_rel |
| Relapse cases: Pulmonary, clinically diagnosed | TB_ret_rel_clindx |
| Relapse cases: extrapulmonary | TB_ret_rel_ep |
| Relapse cases: Pulmonary, bacteriologically confirmed | TB_ret_rel_labconf |
| Retreatment cases: treatment after default (pulmonary smear and/or culture positive) | TB_ret_tad |
| Retreatment cases: treatment after failure (pulmonary smear and/or culture positive) | TB_ret_taf |
| Confirmed cases of RR-/MDR-TB | TB_rr_mdr |
| Second-line drug susceptibility testing (DST) available | TB_sldst_avail |
| Tuberculosis - new and relapse cases | TB_tot_newrel |
| Monitor | TOBACCO_0000000186 |
| Protect from tobacco smoke | TOBACCO_0000000187 |
| Offer help to quit tobacco use | TOBACCO_0000000188 |
| Warn about the dangers of tobacco | TOBACCO_0000000189 |
| Enforce bans on tobacco advertising | TOBACCO_0000000190 |
| Raise taxes on tobacco | TOBACCO_0000000191 |
| Prevalence of smoking any tobacco product among persons aged >= 15 years | TOBACCO_0000000192 |
| Daily smoking of any tobacco product (age-standardized rate) | TOBACCO_0000000193 |
| Current smoking of cigarettes (age-standardized rate) | TOBACCO_0000000194 |
| Daily smoking of cigarettes (age-standardized rate) | TOBACCO_0000000195 |
| Health-care facilities (national legislation) | TOBACCO_0000000196 |
| Education facilities except universities (national legislation) | TOBACCO_0000000197 |
| Universities (national legislation) | TOBACCO_0000000198 |
| Government facilities (national legislation) | TOBACCO_0000000199 |
| Indoor offices (national legislation) | TOBACCO_0000000200 |
| Restaurants (national legislation) | TOBACCO_0000000201 |
| Pubs and bars (national legislation) | TOBACCO_0000000202 |
| Public transport (national legislation) | TOBACCO_0000000203 |
| All other indoor public places (national legislation) | TOBACCO_0000000204 |
| Number of places smoke-free (national legislation) | TOBACCO_0000000205 |
| Compliance with regulations on smoke-free environments (national legislation) | TOBACCO_0000000206 |
| Subnational smoke-free legislation authority exists | TOBACCO_0000000207 |
| Comprehensive bans in place subnationally | TOBACCO_0000000208 |
| Fines for violations | TOBACCO_0000000209 |
| Fines on the establishment | TOBACCO_0000000210 |
| Fines on the patron | TOBACCO_0000000211 |
| Dedicated funds for enforcement | TOBACCO_0000000212 |
| Citizen complaints and investigations | TOBACCO_0000000213 |
| Current smoking of any tobacco product (crude rate) | TOBACCO_0000000337 |
| Daily smoking of any tobacco product (crude rate) | TOBACCO_0000000338 |
| Current smoking of cigarettes (crude rate) | TOBACCO_0000000339 |
| Daily smoking of cigarettes (crude rate) | TOBACCO_0000000340 |
| Current users of any smokeless tobacco product (crude rate) | TOBACCO_0000000341 |
| Daily users of any smokeless tobacco product (crude rate) | TOBACCO_0000000342 |
| Ever users of any smokeless tobacco product (crude rate) | TOBACCO_0000000343 |
| Prevalence of current tobacco use among adolescents aged 13-15 years | TOBACCO_0000000344 |
| Current smokers of cigarettes (youth rate) | TOBACCO_0000000345 |
| Exposure to smoke at home | TOBACCO_0000000346 |
| Exposure to smoke outside home | TOBACCO_0000000347 |
| Jurisdiction name | TOBACCO_0000000348 |
| Number of people covered by subnational legislation | TOBACCO_0000000349 |
| Proportion of national population covered by subnational legislation | TOBACCO_0000000350 |
| Number of places smoke-free (subnational legislation) | TOBACCO_0000000351 |
| Health-care facilities (subnational legislation) | TOBACCO_0000000352 |
| Education facilities, except universities (subnational legislation) | TOBACCO_0000000353 |
| Universities (subnational legislation) | TOBACCO_0000000354 |
| Government facilities (subnational legislation) | TOBACCO_0000000355 |
| Indoor offices (subnational legislation) | TOBACCO_0000000356 |
| Restaurants (subnational legislation) | TOBACCO_0000000357 |
| Pubs and bars (subnational legislation) | TOBACCO_0000000358 |
| Public transport (subnational legislation) | TOBACCO_0000000359 |
| All other indoor public places (subnational legislation) | TOBACCO_0000000360 |
| Access to a toll-free quit line | TOBACCO_0000000361 |
| Smoking cessation support is available in hospitals | TOBACCO_0000000362 |
| Smoking cessation support is available in health clinics or other primary care facilities | TOBACCO_0000000363 |
| Smoking cessation support is available in offices of health professionals | TOBACCO_0000000364 |
| Smoking cessation support is available in the community | TOBACCO_0000000365 |
| Smoking cessation support is available in other settings | TOBACCO_0000000366 |
| Nicotine replacement therapy - legally sold | TOBACCO_0000000367 |
| Nicotine replacement therapy - place available | TOBACCO_0000000368 |
| Bupropion - legally sold | TOBACCO_0000000369 |
| Bupropion - place available | TOBACCO_0000000370 |
| Varenicline - legally sold | TOBACCO_0000000371 |
| Varenicline - place available | TOBACCO_0000000372 |
| Ban on deceitful terms on cigarette packaging | TOBACCO_0000000373 |
| Percentage of principal display area mandated to be covered by health warnings - front and back of cigarette packaging | TOBACCO_0000000374 |
| Percentage of principal display area mandated to be covered by health warnings - front of cigarette packaging | TOBACCO_0000000375 |
| Percentage of principal display area mandated to be covered by health warnings - back of cigarette packaging | TOBACCO_0000000376 |
| Specific health warnings are mandated for cigarette packaging | TOBACCO_0000000377 |
| Number of health warnings approved by the law for cigarette packaging | TOBACCO_0000000378 |
| Health warnings appear on each cigarette package and any outside packaging and labelling used in the retail sale | TOBACCO_0000000379 |
| Health warnings on cigarette packaging describe the harmful effects of tobacco use on health | TOBACCO_0000000380 |
| Font style, font size and colour of health warnings are mandated for cigarette packaging | TOBACCO_0000000381 |
| Health warnings on cigarette packaging must be rotated | TOBACCO_0000000382 |
| Health warnings on cigarette packaging must be written in the principal language(s) of the country | TOBACCO_0000000383 |
| Health warnings on cigarette packaging must include a photograph or graphic | TOBACCO_0000000384 |
| Ban on deceitful terms on other smoked tobacco packaging | TOBACCO_0000000385 |
| Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging | TOBACCO_0000000386 |
| Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging | TOBACCO_0000000387 |
| Specific health warnings are mandated for other smoked tobacco packaging | TOBACCO_0000000388 |
| Number of health warnings approved by the law for other smoked tobacco packaging | TOBACCO_0000000389 |
| Health warnings on other smoked tobacco packaging must be rotated | TOBACCO_0000000390 |
| Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging | TOBACCO_0000000391 |
| Health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale | TOBACCO_0000000392 |
| Health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health | TOBACCO_0000000393 |
| Font style, font size and colour of health warnings are mandated for other smoked tobacco packaging | TOBACCO_0000000394 |
| Health warnings on other smoked tobacco packaging must be written in the principal language(s) of the country | TOBACCO_0000000395 |
| Health warnings on other smoked tobacco packaging must include a photograph or graphic | TOBACCO_0000000396 |
| Ban on deceitful terms on smokeless tobacco packaging | TOBACCO_0000000397 |
| Percentage of principal display area mandated to be covered by health warnings - front and back of smokeless tobacco packaging | TOBACCO_0000000398 |
| Percentage of principal display area mandated to be covered by health warnings - front of smokeless tobacco packaging | TOBACCO_0000000399 |
| Percentage of principal display area mandated to be covered by health warnings - back of smokeless tobacco packaging | TOBACCO_0000000400 |
| Specific health warnings are mandated for smokeless tobacco packaging | TOBACCO_0000000401 |
| Number of health warnings approved by the law for smokeless tobacco packaging | TOBACCO_0000000402 |
| Health warnings appear on each smokeless tobacco package and any outside packaging and labelling used in the retail sale | TOBACCO_0000000403 |
| Health warnings on smokeless tobacco packaging describe the harmful effects of tobacco use on health | TOBACCO_0000000404 |
| Font style, font size and colour of health warnings are mandated for smokeless tobacco packaging | TOBACCO_0000000405 |
| Health warnings on smokeless tobacco packaging must be rotated | TOBACCO_0000000406 |
| Most sold brand of bidis - price in US$ at official exchange rates | TOBACCO_0000000407 |
| Cheapest brand of bidis - currency reported | TOBACCO_0000000408 |
| Cheapest brand of bidis - price in currency reported | TOBACCO_0000000409 |
| Cheapest brand of bidis - price in US$ at official exchange rates | TOBACCO_0000000410 |
| Health warnings on smokeless tobacco packaging must be written in the principal language(s) of the country | TOBACCO_0000000411 |
| Health warnings on smokeless tobacco packaging must include a photograph or graphic | TOBACCO_0000000412 |
| Billboard and outdoor advertising | TOBACCO_0000000413 |
| International magazines and newspapers | TOBACCO_0000000414 |
| International television and radio | TOBACCO_0000000415 |
| Internet | TOBACCO_0000000416 |
| Local magazines and newspapers | TOBACCO_0000000417 |
| National television and radio | TOBACCO_0000000418 |
| Point of sale | TOBACCO_0000000419 |
| Subnational bans on tobacco advertising, promotion and sponsorship | TOBACCO_0000000420 |
| Compliance with bans on direct advertising | TOBACCO_0000000421 |
| Appearance of tobacco products in TV and/or films | TOBACCO_0000000422 |
| Brand name of non-tobacco products used for tobacco product | TOBACCO_0000000423 |
| Free distribution in mail or through other means | TOBACCO_0000000424 |
| Non-tobacco products identified with tobacco brand names | TOBACCO_0000000425 |
| Promotional discounts | TOBACCO_0000000426 |
| Sponsored events | TOBACCO_0000000427 |
| Compliance with bans on promotion and sponsorship | TOBACCO_0000000428 |
| Most sold brand of cigarettes - currency reported | TOBACCO_0000000429 |
| Most sold brand of cigarettes - price in currency reported | TOBACCO_0000000430 |
| Most sold brand of cigarettes - price in US$ at official exchange rates | TOBACCO_0000000431 |
| Cheapest brand of cigarettes - currency reported | TOBACCO_0000000432 |
| Cheapest brand of cigarettes - price in currency reported | TOBACCO_0000000433 |
| Cheapest brand of cigarettes - price in US$ at official exchange rates | TOBACCO_0000000434 |
| Most sold brand of bidis - currency reported | TOBACCO_0000000435 |
| Most sold brand of bidis - price in currency reported | TOBACCO_0000000436 |
| Most sold brand of cigarettes - taxes as a % of price - ad valorem excise | TOBACCO_0000000437 |
| Most sold brand of cigarettes - taxes as a % of price - import duties | TOBACCO_0000000438 |
| Most sold brand of cigarettes - taxes as a % of price - specific excise | TOBACCO_0000000439 |
| Most sold brand of cigarettes - taxes as a % of price - total tax | TOBACCO_0000000440 |
| Cheapest brand of cigarettes - taxes as a % of price - ad valorem excise | TOBACCO_0000000441 |
| Cheapest brand of cigarettes - taxes as a % of price - import duties | TOBACCO_0000000442 |
| Cheapest brand of cigarettes - taxes as a % of price - specific excise | TOBACCO_0000000443 |
| Cheapest brand of cigarettes - taxes as a % of price - total tax | TOBACCO_0000000444 |
| Most sold brand of bidis - taxes as a % of price - ad valorem excise | TOBACCO_0000000445 |
| Most sold brand of bidis - taxes as a % of price - import duties | TOBACCO_0000000446 |
| Most sold brand of bidis - taxes as a % of price - specific excise | TOBACCO_0000000447 |
| Most sold brand of bidis - taxes as a % of price - total tax | TOBACCO_0000000448 |
| Cheapest brand of bidis - taxes as a % of price - ad valorem excise | TOBACCO_0000000449 |
| Cheapest brand of bidis - taxes as a % of price - import duties | TOBACCO_0000000450 |
| Cheapest brand of bidis - taxes as a % of price - specific excise | TOBACCO_0000000451 |
| Cheapest brand of bidis - taxes as a % of price - total tax | TOBACCO_0000000452 |
| Government objectives on tobacco control exist | TOBACCO_0000000453 |
| National agency for tobacco control exists | TOBACCO_0000000454 |
| Number of full-time equivalent staff in national agency | TOBACCO_0000000455 |
| Annual budget for tobacco control in currency reported | TOBACCO_0000000456 |
| Reported currency | TOBACCO_0000000457 |
| Annual budget for tobacco control in US$ at official exchange rate | TOBACCO_0000000458 |
| Budget year | TOBACCO_0000000459 |
| Year of survey of adults | TOBACCO_0000000502 |
| Representativeness of survey of adults | TOBACCO_0000000503 |
| Repeating interval for survey of adults (years) | TOBACCO_0000000504 |
| Year of survey of youth | TOBACCO_0000000505 |
| Representativeness of youth survey | TOBACCO_0000000506 |
| Repeating interval for survey of youth (years) | TOBACCO_0000000507 |
| Most sold brand of cigarettes - taxes as a % of price - value added tax | TOBACCO_0000000508 |
| Most sold brand of cigarettes - taxes as a % of price - other taxes | TOBACCO_0000000509 |
| Most sold brand of bidis - taxes as a % of price - value added tax | TOBACCO_0000000524 |
| Most sold brand of bidis - taxes as a % of price - other taxes | TOBACCO_0000000525 |
| Anti-tobacco mass media campaigns | TOBACCO_0000000526 |
| National tobacco control programmes | TOBACCO_0000000527 |
| Survey age range | TOBACCO_0000000528 |
| Law mandates that health warnings appear on tobacco packages | TOBACCO_0000000529 |
| Health warnings on cigarette packaging must be placed at the top of the principal display areas of the package | TOBACCO_0000000530 |
| Health warnings on cigarette packaging do not remove or diminish the liability of the tobacco industry | TOBACCO_0000000531 |
| Health warnings on cigarette packaging law applys to products whether manufactured domestically imported AND for duty-free sale | TOBACCO_0000000532 |
| Health warnings on cigarette packaging must not be obscured in any way including by required markings such as tax stamps | TOBACCO_0000000533 |
| Health warnings on cigarette packaging law requires or establishes fines for violations | TOBACCO_0000000534 |
| Cigarette packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors | TOBACCO_0000000535 |
| Cigarette packaging and labelling must not use descriptors depicting flavours | TOBACCO_0000000536 |
| Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark | TOBACCO_0000000537 |
| The quit line number must appear on cigarette packaging or labelling | TOBACCO_0000000538 |
| Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) | TOBACCO_0000000539 |
| Law mandates that health warnings appear on smokeless tobacco packages | TOBACCO_0000000540 |
| Health warnings on smokeless tobacco packaging must be placed at the top of the principal display areas of the package | TOBACCO_0000000541 |
| Health warnings on smokeless tobacco packaging do not remove or diminish the liability of the tobacco industry | TOBACCO_0000000542 |
| Health warnings on smokeless tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale | TOBACCO_0000000543 |
| Health warnings on smokeless tobacco packaging must not be obscured in any way including by required markings such as tax stamps | TOBACCO_0000000544 |
| Health warnings on smokeless tobacco packaging law requires or establishes fines for violations | TOBACCO_0000000545 |
| Smokeless tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors | TOBACCO_0000000546 |
| Smokeless tobacco packaging and labelling must not use descriptors depicting flavours | TOBACCO_0000000547 |
| Smokeless tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark | TOBACCO_0000000548 |
| The quit line number must appear on smokeless tobacco packaging or labelling | TOBACCO_0000000549 |
| Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited) | TOBACCO_0000000550 |
| At least one national mass media campaign ran during the survey period | TOBACCO_0000000551 |
| Campaign was part of a comprehensive tobacco control programme | TOBACCO_0000000552 |
| Campaign was pre-tested | TOBACCO_0000000553 |
| Formative research was conducted | TOBACCO_0000000554 |
| Campaign utilized media planning | TOBACCO_0000000555 |
| Earned media/public relations were used to promote the campaign | TOBACCO_0000000556 |
| Process evaluation was employed to assess implementation | TOBACCO_0000000557 |
| Outcome evaluation was employed to assess effectiveness | TOBACCO_0000000558 |
| Ban on appearance of tobacco brands in TV and/or films (product placement) | TOBACCO_0000000559 |
| Most sold brand of cigarettes - price in international dollars | TOBACCO_0000000560 |
| Cheapest brand of cigarettes - price in international dollars | TOBACCO_0000000561 |
| Most sold brand of bidis - price in international dollars | TOBACCO_0000000562 |
| Tobacco excises increased over the survey period | TOBACCO_0000000563 |
| Deaths attributable to the environment | TOTENV_1 |
| Total environment attributable DALYs per 100’000 children under 5 years | TOTENV_10 |
| Deaths attributable to the environment in children under 5 years (%) | TOTENV_11 |
| DALYs attributable to the environment in children under 5 years (%) | TOTENV_12 |
| Age-standardized deaths attributable to the environment (per 100 000 population) | TOTENV_2 |
| Disability-adjusted life years (DALYs) attributable to the environment | TOTENV_3 |
| Age-standardized DALYs attributable to the environment (per 100 000 population) | TOTENV_4 |
| Deaths attributable to the environment (%) | TOTENV_5 |
| Disability-adjusted life years (DALYs) attributable to the environment (%) | TOTENV_6 |
| Total environment attributable deaths (’000) in children under 5 years | TOTENV_7 |
| Total environment attributable deaths per 100’000 children under 5 years | TOTENV_8 |
| Total environment attributable DALYs (’000) in children under 5 years | TOTENV_9 |
| UV radiation | UV_1 |
| UV radiation attributable deaths | UV_2 |
| UV radiation attributable DALYs (’000) | UV_3 |
| UV radiation attributable deaths per 100’000 capita | UV_4 |
| UV radiation attributable DALYs per 100’000 capita | UV_5 |
| Bullied, past 30 days (%) | VIOLENCE_BULLIED |
| Lifetime prevalence of child emotional abuse (%) | VIOLENCE_CHILD_EMOTIONAL |
| Lifetime prevalence of child physical neglect (%) | VIOLENCE_CHILD_NEGLECT |
| Lifetime prevalence of child physical abuse (%) | VIOLENCE_CHILD_PHYSICAL |
| Lifetime prevalence of child sexual abuse (%) | VIOLENCE_CHILD_SEXUAL |
| Extent of implementation of mental health services for victims of all types of violence | VIOLENCE_EXTENTIMP_ALLTYPES |
| Child maltreatment: Extent of implementation of home-visiting programmes | VIOLENCE_EXTENTIMP_CHILDHOMEVISIT |
| Extent of implementation of child protection services | VIOLENCE_EXTENTIMP_CHILDPROTECTION |
| Elder abuse: Extent of implementation of caregiver-support programmes | VIOLENCE_EXTENTIMP_ELDERCAREGIVER |
| Intimate partner violence: Extent of implementation of dating violence prevention programmes | VIOLENCE_EXTENTIMP_PARTNERVIOLPREVENTION |
| Extent of implementation of medico-legal services for victims of sexual violence | VIOLENCE_EXTENTIMP_VICTIMSMEDICOLEGAL |
| Youth violence: Extent of implementation of life-skills and social development programmes | VIOLENCE_EXTENTIMP_YOUTHLIFESKILLS |
| Estimates of number of homicides | VIOLENCE_HOMICIDENUM |
| Estimates of rates of homicides per 100 000 population | VIOLENCE_HOMICIDERATE |
| Physical fighting, past 12 months (%) | VIOLENCE_PHYSICAL_FIGHTING |
| Anti-tobacco mass media campaigns | W-MM_Group |
| Do the health warnings on cigarette packaging include a photograph or graphic? | W10_graphic_A |
| Do the health warnings on other smoked tobacco packaging include a photograph or graphic? | W10_graphic_B |
| Do the health warnings on smokeless tobacco packaging include a photograph or graphic? | W10_graphic_C |
| Do health warnings appear on each cigarette package and any outside packaging and labelling used in the retail sale? | W11_outside_pack_A |
| Do health warnings appear on each other smoked tobacco package and any outside packaging and labelling used in the retail sale? | W11_outside_pack_B |
| Do health warnings appear on each smokeless tobacco package and any outside packaging and labelling used in the retail sale? | W11_outside_pack_C |
| Health warnings on cigarette packaging law applys to products whether manufactured domestically imported AND for duty-free sale | W12_imports_dutyfree_A |
| Health warnings on other smoked tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale | W12_imports_dutyfree_B |
| Health warnings on smokeless tobacco packaging law applys to products whether manufactured domestically imported AND for duty-free sale | W12_imports_dutyfree_C |
| Health warnings on cigarette packaging do not remove or diminish the liability of the tobacco industry | W13_ind_liability_A |
| Health warnings on other smoked tobacco packaging do not remove or diminish the liability of the tobacco industry | W13_ind_liability_B |
| Health warnings on smokeless tobacco packaging do not remove or diminish the liability of the tobacco industry | W13_ind_liability_C |
| Do health warnings on cigarette packaging describe the harmful effects of tobacco use on health? | W14_harm_effects_A |
| Do health warnings on other smoked tobacco packaging describe the harmful effects of tobacco use on health? | W14_harm_effects_B |
| Do health warnings on smokeless tobacco packaging describe the harmful effects of tobacco use on health? | W14_harm_effects_C |
| Does the law mandate specific health warnings on cigarette packaging? | W15_specific_hw_A |
| Does the law mandate specific health warnings on other smoked tobacco packaging? | W15_specific_hw_B |
| Does the law mandate specific health warnings on smokeless tobacco packaging? | W15_specific_hw_C |
| How many health warnings are approved by the law for cigarette packaging? | W16_number_hw_A |
| How many health warnings are approved by the law for other smoked tobacco packaging? | W16_number_hw_B |
| How many health warnings are approved by the law for smokeless tobacco packaging? | W16_number_hw_C |
| Health warnings on cigarette packaging law requires or establishes fines for violations | W17_fines_A |
| Health warnings on other smoked tobacco packaging law requires or establishes fines for violations | W17_fines_B |
| Health warnings on smokeless tobacco packaging law requires or establishes fines for violations | W17_fines_C |
| Ban on deceitful terms on cigarette packaging | W18_misleading_terms_A |
| Ban on deceitful terms on other smoked tobacco packaging | W18_misleading_terms_B |
| Ban on deceitful terms on smokeless tobacco packaging | W18_misleading_terms_C |
| Other smoked tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors | W19_Bolours_numbers_B |
| Cigarette packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors | W19_colours_numbers_A |
| Other smoked tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors | W19_colours_numbers_B |
| Smokeless tobacco packaging and labelling must not use figurative or other signs including colors or numbers as substitutes for prohibited misleading terms and descriptors | W19_colours_numbers_C |
| Law mandates that health warnings appear on tobacco packages | W1_HW_law_A |
| Law mandates that health warnings appear on other smoked tobacco packages | W1_HW_law_B |
| Law mandates that health warnings appear on smokeless tobacco packages | W1_HW_law_C |
| Cigarette packaging and labelling must not use descriptors depicting flavours | W20_flavours_A |
| Other smoked tobacco packaging and labelling must not use descriptors depicting flavours | W20_flavours_B |
| Smokeless tobacco packaging and labelling must not use descriptors depicting flavours | W20_flavours_C |
| Cigarette packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark | W21_emissions_A |
| Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark | W21_emissions_B |
| Other smoked tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark | W21_emissions_quant_B |
| Smokeless tobacco packaging and labelling must not display quantitative information on emission yields (such as tar nicotine and carbon monoxide) including when used as part of a brand name or trademark | W21_emissions_quant_C |
| Cigarette packaging and labelling must display qualitative information on relevant constituents and emissions | W22_emissions_qual_A |
| Other smoked tobacco packaging and labelling must display qualitative information on relevant constituents and emissions | W22_emissions_qual_B |
| Smokeless tobacco packaging and labelling must display qualitative information on relevant constituents and emissions | W22_emissions_qual_C |
| Cigarette packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas | W23_emissions_front_back_A |
| Other smoked tobacco packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas | W23_emissions_front_back_B |
| Smokeless tobacco packaging and labelling must display qualitative information on constituents and emissions on one or more of the principal display areas | W23_emissions_front_back_C |
| Cigarette packaging and labelling must not display expiry dates | W24_exp_date_A |
| Other smoked tobacco packaging and labelling must not display expiry dates | W24_exp_date_B |
| Smokeless tobacco packaging and labelling must not display expiry dates | W24_exp_date_C |
| The quit line number must appear on cigarette packaging or labelling | W25_quitline_number_A |
| The quit line number must appear on other smoked tobacco packaging or labelling | W25_quitline_number_B |
| The quit line number must appear on smokeless tobacco packaging or labelling | W25_quitline_number_C |
| Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). | W26_plainSPACEpackaging_A |
| Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). | W26_plainSPACEpackaging_C |
| Plain packaging of cigarettes is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). | W26_plain_packaging_A |
| Plain packaging of other smoked tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). | W26_plain_packaging_B |
| Plain packaging of smokeless tobacco products is mandatory (ie. the use of logos colours brand images or promotional information on packaging other than brand names and product names displayed in a standard colour and font style is prohibited). | W26_plain_packaging_C |
| The sale of all smokeless tobacco products is completely banned | W27_smokeless_prod_ban |
| Percentage of principal display area mandated to be covered by health warnings - front and back of cigarette packaging | W2_pc_front_back_A |
| Percentage of principal display area mandated to be covered by health warnings - front and back of other smoked tobacco packaging | W2_pc_front_back_B |
| Percentage of principal display area mandated to be covered by health warnings - front and back of smokeless tobacco packaging | W2_pc_front_back_C |
| Percentage of principal display area mandated to be covered by health warnings - front of cigarette packaging | W3_pc_front_A |
| Percentage of principal display area mandated to be covered by health warnings - front of other smoked tobacco packaging | W3_pc_front_B |
| Percentage of principal display area mandated to be covered by health warnings - front of smokeless tobacco packaging | W3_pc_front_C |
| Percentage of principal display area mandated to be covered by health warnings - back of cigarette packaging | W4_pc_back_A |
| Percentage of principal display area mandated to be covered by health warnings - back of other smoked tobacco packaging | W4_pc_back_B |
| Percentage of principal display area mandated to be covered by health warnings - back of smokeless tobacco packaging | W4_pc_back_C |
| Health warnings on cigarette packaging must be placed at the top of the principal display areas of the package | W5_top_side_A |
| Health warnings on other smoked tobacco packaging must be placed at the top of the principal display areas of the package | W5_top_side_B |
| Health warnings on smokeless tobacco packaging must be placed at the top of the principal display areas of the package | W5_top_side_C |
| Does the law mandate font style, font size and colour of health warnings on cigarette packaging? | W6_font_A |
| Does the law mandate font style, font size and colour of health warnings on other smoked tobacco packaging? | W6_font_B |
| Does the law mandate font style, font size and colour of health warnings on smokeless tobacco packaging? | W6_font_C |
| Are the health warnings on cigarette packaging rotating? | W7_rotation_A |
| Are the health warnings on other smoked tobacco packaging rotating? | W7_rotation_B |
| Are the health warnings on smokeless tobacco packaging rotating? | W7_rotation_C |
| Are the health warnings on cigarette packaging written in the principal language(s) of the country? | W8_princ_langs_A |
| Are the health warnings on other smoked tobacco packaging written in the principal language(s) of the country? | W8_princ_langs_B |
| Are the health warnings on smokeless tobacco packaging written in the principal language(s) of the country? | W8_princ_langs_C |
| Health warnings on cigarette packaging must not be obscured in any way including by required markings such as tax stamps | W9_no_obscure_A |
| Health warnings on other smoked tobacco packaging must not be obscured in any way including by required markings such as tax stamps | W9_no_obscure_B |
| Health warnings on smokeless tobacco packaging must not be obscured in any way including by required markings such as tax stamps | W9_no_obscure_C |
| Access to improved drinking water sources | WAS_0000000001 |
| Access to improved sanitation | WAS_0000000002 |
| Life expectancy at birth (years) | WHOSIS_000001 |
| Healthy life expectancy (HALE) at birth (years) | WHOSIS_000002 |
| Neonatal mortality rate (per 1000 live births) | WHOSIS_000003 |
| Adult mortality rate (probability of dying between 15 and 60 years per 1000 population) | WHOSIS_000004 |
| Low-birth-weight newborns (%) | WHOSIS_000005 |
| Infants exclusively breastfed for the first six months of life (%) | WHOSIS_000006 |
| Healthy life expectancy (HALE) at age 60 (years) | WHOSIS_000007 |
| Children aged <5 years underweight (%) | WHOSIS_000008 |
| Children aged <5 years overweight (%) | WHOSIS_000009 |
| Adults aged ≥ 20 years who are obese (%) | WHOSIS_000010 |
| Alcohol consumption among adults aged ≥ 15 years (litres of pure alcohol per person per year) | WHOSIS_000011 |
| Prevalence of smoking any tobacco product among adults (≥15 years) (%) | WHOSIS_000012 |
| Prevalence of current tobacco use among adolescents (13-15 years) (%) | WHOSIS_000013 |
| Stillbirth rate (per 1000 total births) | WHOSIS_000014 |
| Life expectancy at age 60 (years) | WHOSIS_000015 |
| Most recent census (year) | WHS10_1 |
| International Statistical Classification of Diseases and Related Health Problems (ICD) | WHS10_10 |
| Number of cause-of-death registration years available | WHS10_2 |
| Number of national population surveys - child anthropometry | WHS10_3 |
| Number of national population surveys - child mortality | WHS10_4 |
| Number of national population surveys - maternal mortality | WHS10_5 |
| Number of national population surveys - HIV prevalence | WHS10_6 |
| Number of national population surveys - adult health | WHS10_7 |
| Civil registration coverage of cause-of-death (%) | WHS10_8 |
| Ill-defined causes in cause-of-death registration (%) | WHS10_9 |
| Distribution of years of life lost by major cause group | WHS2_126 |
| Age-standardized mortality rate by cause (per 100 000 population) | WHS2_131 |
| Deaths due to HIV/AIDS (per 100 000 population) | WHS2_138 |
| Deaths due to malaria (per 100 000 population) | WHS2_152 |
| Distribution of causes of death among children aged <5 years (%) | WHS2_155 |
| Age-standardized mortality rate by cause (per 100 000 population) - Cancer | WHS2_160 |
| Age-standardized mortality rate by cause (per 100 000 population) - Cardiovascular | WHS2_161 |
| Age-standardized mortality rate by cause (per 100 000 population) - Injuries | WHS2_162 |
| Age-standardized mortality rate by cause (per 100 000 population) - Noncommunicable | WHS2_163 |
| Distribution of causes of death among children aged <5 years (%) - Malaria | WHS2_164 |
| Distribution of causes of death among children aged <5 years (%) - Pneumonia | WHS2_165 |
| Distribution of causes of death among children aged <5 years (%) - Injuries | WHS2_166 |
| Distribution of causes of death among children aged <5 years (%) - Diarrhoea | WHS2_167 |
| Distribution of causes of death among children aged <5 years (%) - Measles | WHS2_168 |
| Distribution of causes of death among children aged <5 years (%) - Causes arising in the perinatal period | WHS2_169 |
| Distribution of causes of death among children aged <5 years (%) - HIV/AIDS | WHS2_170 |
| Distribution of causes of death among children aged <5 years (%) - Other diseases | WHS2_171 |
| Distribution of years of life lost by broader causes (%) - Communicable | WHS2_172 |
| Distribution of years of life lost by broader causes (%) - Noncommunicable | WHS2_173 |
| Distribution of years of life lost by broader causes (%) - Injuries | WHS2_174 |
| Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - All causes | WHS2_3070_all |
| Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - Cancer | WHS2_3070_cancer |
| Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - Cardiovasular disease and diabetes | WHS2_3070_cdd |
| Age-standardized mortality rate by cause (ages 30-70, per 100 000 population) - Chronic respiratory conditions | WHS2_3070_chronic |
| Age-standardized mortality rate by cause (per 100 000 population) - Communicable | WHS2_513 |
| Distribution of causes of death among children aged <5 years (%) - Prematurity | WHS2_514 |
| Distribution of causes of death among children aged <5 years (%) - Neonatal sepsis | WHS2_515 |
| Distribution of causes of death among children aged <5 years (%) - Congenital anomalies | WHS2_516 |
| Distribution of causes of death among children aged <5 years (%) - Birth asphyxia | WHS2_523 |
| Cholera - number of reported cases | WHS3_40 |
| Diphtheria - number of reported cases | WHS3_41 |
| Japanese encephalitis - number of reported cases | WHS3_42 |
| Pertussis - number of reported cases | WHS3_43 |
| Leprosy - number of reported cases | WHS3_45 |
| Total tetanus - number of reported cases | WHS3_46 |
| Meningitis - number of reported cases | WHS3_47 |
| Malaria - number of reported confirmed cases | WHS3_48 |
| Poliomyelitis - number of reported cases | WHS3_49 |
| Yellow fever - number of reported cases | WHS3_50 |
| H5N1 influenza - number of reported cases | WHS3_51 |
| Plague - number of reported cases | WHS3_52 |
| Number of reported cases of tuberculosis | WHS3_522 |
| Mumps - number of reported cases | WHS3_53 |
| Number of reported cases of tuberculosis (DOTS) | WHS3_54 |
| Congenital Rubella Syndrome - number of reported cases | WHS3_55 |
| Neonatal tetanus - number of reported cases | WHS3_56 |
| Rubella - number of reported cases | WHS3_57 |
| Measles - number of reported cases | WHS3_62 |
| Diphtheria tetanus toxoid and pertussis (DTP3) immunization coverage among 1-year-olds (%) | WHS4_100 |
| Children aged <5 years with ARI symptoms taken to a health facility (%) | WHS4_106 |
| Children aged <5 years with diarrhoea receiving ORT (%) | WHS4_107 |
| Children aged <5 years with ARI symptoms who took antibiotic treatment (%) | WHS4_108 |
| Antenatal care coverage - at least one visit (%) | WHS4_111 |
| Antenatal care coverage - at least one visit, among girls aged 15-19 (%) | WHS4_111_AGE1519 |
| Births by caesarean section (%) | WHS4_115 |
| Hepatitis B (HepB3) immunization coverage among 1-year-olds (%) | WHS4_117 |
| Children aged 6-59 months who received vitamin A supplementation (%) | WHS4_124 |
| Neonates protected at birth against neonatal tetanus (PAB) (%) | WHS4_128 |
| Hib (Hib3) immunization coverage among 1-year-olds (%) | WHS4_129 |
| Antenatal care coverage - at least four visits (%) | WHS4_154 |
| Postnatal care visit within two days of birth (%) | WHS4_2530 |
| BCG immunization coverage among 1-year-olds (%) | WHS4_543 |
| Polio (Pol3) immunization coverage among 1-year-olds (%) | WHS4_544 |
| Antiretroviral therapy coverage among HIV-infected pregnant women for PMTCT (%) | WHS4_99 |
| Population using improved drinking-water sources (%) | WHS5_122 |
| Population using improved sanitation facilities (%) | WHS5_158 |
| Population using solid fuels (%) | WHS5_512 |
| Radiotherapy units (per 1 000 000 population) | WHS6_100 |
| Median availability of selected generic medicines (%) - Private | WHS6_101 |
| Hospital beds (per 10 000 population) | WHS6_102 |
| Median consumer price ratio of selected generic medicines - Private | WHS6_116 |
| Number of dentistry personnel | WHS6_123 |
| Physicians density (per 10 000 population) | WHS6_125 |
| Number of nursing and midwifery personnel | WHS6_127 |
| Number of physicians | WHS6_136 |
| Number of community health workers | WHS6_140 |
| Dentistry personnel density (per 10 000 population) | WHS6_144 |
| Nursing and midwifery personnel density (per 10 000 population) | WHS6_148 |
| Community health workers density (per 10 000 population) | WHS6_150 |
| Number of other health service providers | WHS6_157 |
| Other health service providers density (per 10 000 population) | WHS6_159 |
| Number of pharmaceutical personnel | WHS6_517 |
| Number of environment and public health workers | WHS6_518 |
| Density of pharmaceutical personnel (per 10 000 population) | WHS6_519 |
| Density of environment and public health workers (per 10 000 population) | WHS6_520 |
| Private prepaid plans as a percentage of private expenditure on health | WHS7_103 |
| Per capita government expenditure on health at average exchange rate (US$) | WHS7_104 |
| Per capita total expenditure on health (PPP int. $) | WHS7_105 |
| Per capita government expenditure on health (PPP int. $) | WHS7_108 |
| General government expenditure on health as a percentage of total government expenditure | WHS7_113 |
| External resources for health as a percentage of total expenditure on health | WHS7_120 |
| Social security expenditure on health as a percentage of general government expenditure on health | WHS7_134 |
| Out-of-pocket expenditure as a percentage of private expenditure on health | WHS7_139 |
| Total expenditure on health as a percentage of gross domestic product | WHS7_143 |
| Private expenditure on health as a percentage of total expenditure on health | WHS7_147 |
| General government expenditure on health as a percentage of total expenditure on health | WHS7_149 |
| Out-of-pocket expenditure as a percentage of total expenditure on health | WHS7_150 |
| Per capita total expenditure on health at average exchange rate (US$) | WHS7_156 |
| Measles (MCV) immunization coverage among 1-year-olds (%) | WHS8_110 |
| Literacy rate among adults aged >= 15 years (%) | WHS9_85 |
| Population (in thousands) total | WHS9_86 |
| Net primary school enrolment ratio (%) | WHS9_87 |
| Population median age (years) | WHS9_88 |
| Population proportion under 15 (%) | WHS9_89 |
| Population living on <$1 (PPP int. $) a day (%) | WHS9_90 |
| Civil registration coverage of births (%) | WHS9_91 |
| Population proportion over 60 (%) | WHS9_92 |
| Gross national income per capita (PPP int. $) | WHS9_93 |
| Civil registration coverage of causes of deaths (%) | WHS9_94 |
| Total fertility rate (per woman) | WHS9_95 |
| Population living in urban areas (%) | WHS9_96 |
| Annual population growth rate (%) | WHS9_97 |
| Crude birth rate (per 1000 population) | WHS9_CBR |
| Crude death rate (per 1000 population) | WHS9_CDR |
| Cellular subscribers (per 100 population) | WHS9_CS |
| Preterm birth rate (per 100 live births) | WHS_PBR |
| Water, sanitation and hygiene attributable deaths | WSH_1 |
| Water, sanitation and hygiene attributable deaths (’000) in children under 5 years | WSH_2 |
| Water, sanitation and hygiene attributable deaths per 100’000 capita | WSH_3 |
| Water, sanitation and hygiene attributable deaths per 100’000 children under 5 years | WSH_4 |
| Water, sanitation and hygiene attributable DALYs (’000) | WSH_5 |
| Water, sanitation and hygiene attributable DALYs (’000) in children under 5 years | WSH_6 |
| Water, sanitation and hygiene attributable DALYs per 100’000 capita | WSH_7 |
| Water, sanitation and hygiene attributable DALYs per 100’000 children under 5 years | WSH_8 |
| Warn about the dangers of tobacco | W_Group |
| Antenatal care coverage - at least one visit (in the two or three years preceding the survey) (%) | anc1 |
| Antenatal care coverage - at least one visit (in the three years preceding the survey) (%) | anc13 |
| Antenatal care coverage - at least one visit (in the five years preceding the survey) (%) | anc15 |
| Antenatal care coverage - at least four visits (in the two or three years preceding the survey) (%) | anc4 |
| Antenatal care coverage - at least four visits (in the three years preceding the survey) (%) | anc43 |
| Antenatal care coverage - at least four visits (in the five years preceding the survey) (%) | anc45 |
| Adolescent fertility rate (per 1000 women aged 15-19 years) | asfr1 |
| BCG immunization coverage among one-year-olds (%) | bcgv |
| Children aged < 5 years with pneumonia symptoms taken to a health facility (%) | carep |
| Composite coverage index (%) | cci |
| Child mortality rate (probability of dying between age 1 and age 5 per 1000 live births) | cmr |
| Contraceptive prevalence - modern methods (%) | cpmo |
| Contraceptive prevalence - modern and traditional methods (%) | cpmt |
| Births by caesarean section (in the two or three years preceding the survey) (%) | csection |
| Births by caesarean section (in the three years preceding the survey) (%) | csection3 |
| Births by caesarean section (in the five years preceding the survey) (%) | csection5 |
| DTP3 immunization coverage among one-year-olds (%) | dptv |
| Early initiation of breastfeeding (in the two or three years preceding the survey) (%) | ebreast |
| Early initiation of breastfeeding (in the three years preceding the survey) (%) | ebreast3 |
| Early initiation of breastfeeding (in the five years preceding the survey) (%) | ebreast5 |
| Family planning needs satisfied (%) | famplan |
| Demand for family planning satisfied (%) | fps |
| Full immunization coverage among 1-year-olds (%) | full |
| Full immunization coverage among one-year-olds (%) | fullv |
| Infant mortality rate (deaths per 1000 live births) | imr |
| Children aged < 5 years sleeping under insecticide-treated nets (%) | itnch |
| Children aged <5 years sleeping under insecticide-treated nets (%) | itnchild |
| Pregnant women sleeping under insecticide-treated nets (%) | itnpreg |
| Pregnant women sleeping under insecticide-treated nets (%) | itnwm |
| Measles (MCV) immunization coverage among 1-year-olds (%) | measlesv |
| Measles immunization coverage among one-year-olds (%) | mslv |
| Neonatal mortality rate (deaths per 1000 live births) | nmr |
| Prevalence of obesity in non-pregnant women aged 15 - 49 years, BMI >= 30 (%) | obese |
| Prevalence of obesity in non-pregnant women aged 15-49 years, BMI >= 30 (%) | obesewm |
| Children aged < 5 years with diarrhoea receiving oral rehydration salts (%) | ors |
| Children aged < 5 years with diarrhoea receiving oral rehydration therapy and continued feeding (%) | ort |
| Overweight prevalence in children aged <three years (%) | overwgt3 |
| Overweight prevalence in children aged <five years (%) | overwgt5 |
| Postnatal care visit within two days of birth (in the x years preceding the survey) (%) | pncall |
| Postnatal care visit within two days of birth (in the three years preceding the survey) (%) | pncall3 |
| Postnatal care visit within two days of birth (in the five years preceding the survey) (%) | pncall5 |
| Postnatal care visit within two days of birth - born outside a health facility (in the x years preceding the survey) (%) | pnchome |
| Postnatal care visit within two days of birth - born outside a health facility (in the three years preceding the survey) (%) | pnchome3 |
| Postnatal care visit within two days of birth - born outside a health facility (in the five years preceding the survey) (%) | pnchome5 |
| Children aged <5 years with ARI symptoms taken to facility (%) | pneumcare |
| Postneonatal mortality rate (probability of dying between age 30 days and 11 months per 1000 live births) | pnmr |
| Polio immunization coverage among one-year-olds (%) | poliov |
| Births attended by skilled health personnel (in the two or three years preceding the survey) (%) | sba |
| Births attended by skilled health personnel (in the three years preceding the survey) (%) | sba3 |
| Births attended by skilled health personnel (in the five years preceding the survey) (%) | sba5 |
| Children aged <5 years stunted (%) | stunt |
| Stunting prevalence in children aged < 3 years (%) | stunt3 |
| Stunting prevalence in children aged < 5 years (%) | stunt5 |
| Total fertility rate (per woman) | tfr |
| Under-five mortality rate (deaths per 1000 live births) | u5mr |
| Children aged <5 years underweight (%) | uweight |
| Underweight prevalence in children aged < 3 years (%) | uweight3 |
| Underweight prevalence in children aged < 5 years (%) | uweight5 |
| Children aged 6-59 months who received vitamin A supplementation (%) | vita |
| Wasting prevalence in children aged < 3 years (%) | wast3 |
| Wasting prevalence in children aged < 5 years (%) | wast5 |